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ABSTRACT 	  
Ovarian cancer represents an outstanding clinical challenge because of its high mortality 
rate, mainly due to tumor relapse and chemoresistance. The identification of novel targets 
and strategies for the treatment of OC is clearly an unmet need in clinical oncology. In this 
context, drugs that interfere with tumor neovascularization have shown promising results 
in recent clinical trials. However, the beneficial effect of anti-angiogenic therapies is often 
modest and transient: in OC patients, for example, it has been observed only a limited 
increase in progression-free survival. 
Thus, the definition of novel druggable targets within the tumor vasculature will have 
profound implications, particularly for those tumor types, such as OC, that respond poorly 
to conventional anti-cancer treatments. 
L1 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily that 
was initially characterized as an adhesion molecule playing a key role in the development 
of nervous system. However, several studies have demonstrated its involvement in several 
types of human cancer, including ovarian carcinoma. In this context, L1 expression is 
generally associated with poor diagnosis, an aggressive behavior and advanced tumor 
stage. Moreover, L1 induces a motile and invasive phenotype, supporting metastatic 
spread, and promotes chemoresistance. 
Our laboratory has obtained compelling evidence that L1 is aberrantly expressed in tumor 
vasculature and exerts an unexpected, pleiotropic function in endothelial cells.  
Based on these findings and on the pivotal role of angiogenesis in ovarian cancer, in this 
work I have investigate the functional role of L1 within the OC-associated vasculature. My 
results revealed that L1 is particularly abundant in OC vasculature as compared to normal 
vessels. Moreover,, vascular L1 was found to be a causal player in OC progression, 
possibly due to an endothelial cell-autonomous effect on OC vascularization, concomitant 
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to a positive regulation of ovarian cancer stem cell function. 
This research, besides giving insights into novel pathways involved in pathological 
angiogenesis, provides the rationale for exploring the clinical relevance of L1 expression 
and function in OC vessels and in their crosstalk with tumor cells, possibly opening new 
avenues for the development of innovative targeted therapies for OC malignancy. 
	   12	  
 
1. INTRODUCTION 
1.1 Tumor Angiogenesis 
 
During embryonic development new vessels form by assembly of endothelial precursors, 
called angioblasts, which are able to organize a primitive vascular network of small 
capillaries. This process is called vasculogenesis 1. Then, vessel sprouting underlies the 
initial phases of angiogenesis (from the greek angêion, vessels, e genesis, birth), which is 
the formation of new vessels from preexisting blood vessels by proliferation and migration 
of endothelial cells (ECs) in response to a proangiogenic stimulus. This creates a more 
organized vasculature architecture that remodels into arteries and veins 2 (Figure. 1).  
 
 
 
Figure 1. Schematic representation of vessel formation.  
During embryonic development new vessels form by the assembly of endothelial 
progenitors through vasculogenesis. Later, angiogenesis determines the formation of 
additional vessels by proliferation of preexisting ECs. The vascular network is stabilized 
by the recruitment of mural cells (Adapted from Yoh Takuwa et al. 2010, 3). 
 
Subsequently, the newly formed vessels are stabilized by the recruitment of pericytes and 
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vascular smooth muscle cells that enwrap nascent EC tubules 4 and by generating 
extracellular matrix. Collectively these processes result in the maturation and stabilization 
of the vessels. 
In the adult, vessels are quiescent and rarely form new branches. However, ECs maintain 
their plasticity and their ability to respond to angiogenic signals both in physiological 
situations, such as wound healing, in the cycling ovary or in the placenta during pregnancy, 
but also in pathological conditions such as inflammatory disorders and cancer 5.  
In 1971, Judah Folkman first formulated the hypothesis that tumor growth depends on 
angiogenesis 6. Indeed, solid tumors can grow beyond a certain size (~2 mm) only if they 
induce the formation of new blood vessels that supply oxygen and nutrients to cancer cells. 
During tumorigenesis, EC may be re-activated from a resting to a proliferative state by 
several signals, which can be produced by tumor, stromal or immune cells or can be 
mobilized from the extracellular matrix 7. This “angiogenic switch” strictly depends on an 
increased production of pro-angiogenic factors, such as vascular endothelial growth factor 
(VEGF), fibroblast growth factor-2 (FGF-2), placental growth factor (PlGF), transforming 
growth factor-beta (TGFbeta), platelet derived growth factor (PDGF) and angiopoietins 
(Angs). Moreover, this switch may also involve the down-regulation of anti-angiogenic 
modulators such as endostatin. Overall, the imbalance of angiogenic regulators in favor of 
pro-angiogenic stimuli determines the establishment of an “angiogenic state” that results in 
the formation of a chaotic vascular architecture (Figure. 2). The newly formed blood vessel 
network provides tumors with oxygen and nutrients, thus allowing the cancer cells to 
proliferate and form metastases. Indeed, tumor vessels offer a critical route for cancer 
dissemination to distant organs 8. 
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Figure 2. An imbalance between anti- and pro-angiogenic factors resulted in  
uncontrolled neo- vascularization in tumor. 
 In normal tissues ECs are usually quiescent and the action of pro-angiogenic factors is 
balanced by the effects of anti-angiogenic molecules. Conversely, in tumors an 
uncontrolled production of pro-angiogenic factors determines the reactivation of ECs 
which results in the formation of a chaotic vessel network that in turn foster tumor cell 
proliferation (adapted from Sandy Giuliano & Gilles Pagès 2013, 9). 
 
In normal tissues, mature ECs are connected by intercellular junctions that are able to 
stabilize the vessel wall 10. In addition, perivascular cells, including both pericytes and 
vascular smooth muscle cells, firmly interact with ECs to stabilize vessels. Conversely, the 
vasculature associated to tumors is structurally abnormal. Indeed, tumor vessels are highly 
disorganized, tortuous, dilated and heterogeneous in size 11. The ECs lining tumor vessel 
possess an irregular morphology (Figure. 3). Tumor ECs are abnormal in shape, they grow 
on top of each other and project into the lumen. Moreover, vascular endothelium in tumors 
is often leaky, with ECs loosely attached one to the other, and contains several 
fenestrations, resulting in hemorrhage and increased interstitial fluid pressure 12 (Figure. 
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4). These defects, together with poor pericyte coverage and an absent/irregular basement 
membrane deposition, contribute to vascular instability and altered permeability 12,13. 
Consequently, tumor blood flow is chaotic and irregular within the mass. The abnormal 
tumor vasculature favours a tumor microenvironment characterized by an impaired tumor 
oxygenation that, in turn, leads to hypoxia-induced tumor growth and dissemination while 
diminishing the response to therapy and radiation 14. As a matter of fact, the development 
of drugs able to interfere with tumor vessel abnormalities or to block/inactivate the 
function of pro-angiogenic molecules is being actively pursued as a promising therapeutic 
strategy in oncology. 
 
 
Figure 3. Scanning Electron Microscopic (SEM) imaging of normal and tumor vessels.  
(A) SEM imaging of normal microvasculature showing arterioles, capillaries and venules 
gerarchically organized. (B) SEM imaging of tumor microvasculature characterized by 
chaotic organization and the lack of conventional hierarchy of blood vessels. (C) SEM 
imaging of the luminal surface of normal vessel. EC are tightly attached on to the other 
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(arrowed). (D-E) SEM imaging of the luminal surface of tumor vessel. Interendothelial 
contacts are weakened (arrowed), EC protrude into the lumen and contain several 
fenestrations (E) (Adapted from M McDonald & Peter L Choyke 2003, 15) 
 
 
 
Figure 4. Tumor vessels are functionally abnormal.  
(A) In healty tissues vessels are lined by ECs (in yellow) that relay on basement membrane 
(BM, in red) and they are stabilized by perycites (in green). (B )In tumors, ECs are loosely 
attached one to the other, BM is discontinuous and pericytes detached from BM. 
Collectively, these abnormal features establish an irregular and heterogeneous blood flow 
in tumor mass and determin an increase of interstitial fluid pressure (Adapted from Peter 
Carmeliet & Rakesh K. Jain 2011, 11). 
 
 
1. 1. 2 VEGF-based anti-angiogenic therapy in cancer 
The pathophysiological changes affecting tumor vasculature described in paragraph 1. 1 
have several implications on tumor behavior. On one hand, hypoxic tumor cells usually 
have a more aggressive phenotype and they are more prone to metastasize. On the other 
hand, the abnormal blood flow and the irregular distribution of vessels, together with the 
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increased vascular permeability, could also prevent the delivery of systemically 
administered cytotoxics to all areas of the tumor mass. 
The revolutionary concept of treating tumor by inhibiting new blood vessel formation was 
established by Judah Folkman in 1971 6. Indeed, since most tumors cannot grow without a 
blood supply, the general idea was to find ways to block tumor neo-vascularization in 
order to starve it, thus preventing its growth and the development of metastases.  
Research in tumor angiogenesis and anti-angiogenic compounds progressed slowly until 
the discovery of a major angiogenic driver, the vascular endothelial growth factor (VEGF) 
16,17. Over the last decades many investigators have embarked on the design of therapeutic 
strategies that, by interfering with the angiogenic cascade, would prevent cancer growth 
and metastasis 18. The most prominent output of these efforts has been the approval for the 
clinical use of drugs that inhibit the VEGF pathway. The first compound that has been 
approved by FDA in 2004 for clinical purposes was Bevacizumab (Avastin, Genentech), a 
humanized monoclonal antibody targeting VEGF. Thereafter, several small-molecule 
tyrosine kinase inhibitors (TKIs) of VEGFRs have been developed and some of them are 
currently under clinical investigation, such as cediranib 19 and pazopanib 20.  
Early preclinical studies corroborated the hypothesis that inhibiting blood vessels starve 
tumors to death or render them dormant. In 1993, Napoleone Ferrara reported that the 
treatment with anti-VEGF monoclonal antibody of mice bearing xenografts of 
glioblastoma multiforme, leiomyosarcoma or rhabdomyosarcoma caused a decrease in 
vessel density and a significant reduction of tumor growth 21. These results were also 
confirmed by the same group in a mouse model of colorectal cancer 22.  
Despite the exciting and promising results obtained in preclinical models, the use of anti-
VEGF drugs as monotherapy in clinical setting showed modest benefit in terms of survival 
23. However, the combination of VEGF blockade by Bevacizumab with standard 
chemotherapy in phase III trials has yielded improved OS or PFS in metastatic colorectal 
and non-small cell lung cancer patients, thus supporting the rationale of targeting tumor 
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vasculature to improve the efficacy of cytostatic agents 24-28. Since the anti-angiogenic 
therapy aims at reducing blood vessel, this might hamper the efficacy of systemically 
administered chemotherapy, which in fact relies on efficient tumor blood flow. These 
observations might seem in contrast with the improved progression free survival (PFS) and 
overall survival (OS) obtained in clinic by the combination of Bevacizumab with the 
chemotherapy. This apparent “paradox” might be solved by the provocative paradigm of 
“vascular normalization” postulated by Rakesh Jain in 2001 14. He proposed to restore the 
balance between pro- and anti-angiogenic signals back toward a quiescent state by a 
judicious use of anti-angiogenic agents (Figure. 5), mainly represented by anti-VEGF 
drugs. Rather than destroying newly formed tumor vessels, anti-angiogenic therapy should 
take vessel structure and function back to a “normal-like” state.  
 
 
 
Figure 5. Vascular normalization. 
The tumor-associated vasculature is functionally and structurally abnormal. The treatment 
of tumor with an anti-angiogenic drug might revert tumor vessel abnormalities to a more 
normal phenotype reestablishing the balance between pro-angiogenic and anti-angiogenic 
factors (Adapted from Shom Goel et al. 2011, 29). 
 
 
	   19	  
A large number of preclinical studies confirmed the existence of a normalized vessel 
phenotype upon anti-VEGF treatment 30,31. They revealed a reduction in vessel density, 
increased pericyte coverage, improved tumor oxygenation and reduced vascular 
permeability. These reports demonstrated also the existence of a “normalization window”, 
namely a time interval, usually within the first three days of treatment, that begins with the 
appearance of a normalized vasculature and ends with the disappearance of its hallmarks.  
These promising results demonstrating a synergism between anti-VEGF therapy and 
chemotherapy in preclinical models, have fostered a number of clinical studies in human to 
verify whether vascular normalization occurs also in patients 32,33. Even if these studies are 
complex and they have several limits, such as the inability to perform several biopsies and 
at scheduled time points on the same patient, they have provided evidence of vascular 
normalization 34. 
Unfortunately, vascular normalization is a transient phenomenon and the benefits resulting 
from the addition of anti-angiogenic therapy to standard chemotherapy are only temporary. 
In fact, early after the beginning of the anti-angiogenic treatment, tumors develop 
resistance to VEGF therapy and become able to overcome the blockade of angiogenic 
pathways. 
 
1. 1. 3 Possible modes of resistance to anti-angiogenic drugs  
Despite promising results were obtained in preclinical models, the inhibitors of VEGF and 
of its receptor (VEGFR) displayed only partial beneficial effects on certain solid tumors 
and in many cases cancers develop resistance/escape mechanisms or are refractory to 
VEGF blockade 35. A still evolving and not yet definitive hypothesis is that the angiogenic 
tumor adapt to the drug and it can elude the blockade of angiogenesis in several ways 36 
(Figure. 6): 
• activating alternative pro-angiogenic pathways, such as FGF/FGFR signaling, thus 
compensating for the VEGF-blockade (Figure . 6A); 
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• recruiting endothelial/stromal precursors from bone marrow (bone marrow-derived 
cells, BMDCs) that can fuel tumor growth and the angiogenic process in a VEGF-
independent way (Figure. 6B); 
• increasing the pericyte coverage of tumor vessels. The recruitment of these cells 
help vessels in protecting them from death caused by the anti-angiogenic treatment 
(Figure. 6C); 
• selecting clones with a more aggressive behavior and with a higher metastatic 
potential. These clones will be more prone to colonize to normal tissues and form 
distal metastasis to escape oxygen and nutrient deprivation (Figure. 6D). 
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Figure 6. Possible modes of resistance to VEGF-based anti-angiogenic drugs.  
Shortly after the beginning of the treatment with an anti-VEGF drug, tumors may acquire 
resistance to therapy. (A) Tumor cells activate alternative pro-angiogenic pathways that 
compensate for the depletion of VEGF. (B) Tumor recruits endothelial cells from bone 
marrow. (C) Tumor vessels increase their pericyte coverage avoiding the death caused by 
the anti-angiogenic drug. (D) Tumor cells with high invasive and metastatic potential are 
selected, which are able to migrate and colonize other normal tissues (adapted from 
Gabriel Bergers & Douglas Hanahan 2008, 36). 
 
A deeper understanding of the modes of resistance to VEGF-based therapy and the 
underling mechanisms will offer the essential opportunity to improve the benefits of anti-
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angiogenic therapy and to overcame the current limits of such treatments. 
 
1. 1. 4 Current limits of anti-angiogenic drugs and future directions  
 
In addition to the development of resistance/escape mechanisms, the discordance between 
preclinical and clinical studies with regard to the outcome of anti-angiogenic treatments 
can be explained comparing more closely the studies themselves 37: 
1. the preclinical tumor models employed grow rapidly and are more sensitive to anti-
VEGF agents than their human counterparts; 
2. anti-angiogenic therapy was usually used to treat primary tumor in preclinical 
models while almost all anti-angiogenic agents had been approved for metastatic 
diseases in clinic; 
3. while most preclinical studies used these drugs as monotherapies, several anti-
angiogenic compounds showed improved OS only when combined with chemo- or 
immune-therapeutics; 
4. the dose of anti-angiogenic drug utilized in many preclinical studies has been 
incompatible with clinical purposes, possibly leading to misleading results. 
 
In order to obtain results that can be easily transfered into clinic, a more appropriate 
experimental design and preclinical data interpretation is needed.  
In addition, several strategies may help in overcoming the limitations of current anti-
angiogenic treatments. The first aspect to take into account is that a tumor must be 
considered as an organ. Beside tumor cells, it consists of several other cell types, including 
endothelial cells, pericytes, immune cells and fibroblasts, that together form a tumor 
microenvironment able to promote tumor cell proliferation, metastasis and resistance to 
various therapies. Moreover, current antitumor and vascular normalization therapies have 
mainly focused on endothelial cell-dependent angiogenesis, overlooking several other 
mechanisms of neovascularization. It is clear now that tumor vasculature is not necessarily 
dependent of endothelial cell proliferation and sprouting of new capillaries 38. Beside ECs, 
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other cell types actively participate at the formation of tumor vasculature, including stem 
cells, cancer stem cells, BM-derived endothelial progenitors through at least four ways 
38,39:  
1. intussusceptive angiogenesis, where preexisting vessel divided into two new blood 
vessels by the formation of transvascular pillar inside vessel lumen. 
2. blood vessel co-option, in which tumor cells grow along already existing vessel 
without inducing the formation of new capillaries; 
3. vasculogenic mimicry, where tumor cells dedifferentiate into endothelial-like cells 
and start forming tube structures; 
4. mobilizing bone marrow-derived circulating endothelial progenitor cells, which are 
able to assemble into newly blood vessels. 
 
Thus, the concomitant targeting of tumor cells, bone marrow-derived cells, and other 
vasculogenic cells in a tumor microenvironment, as well as targeting more than one 
angiogenic-related pathways at the same time, may improve the efficacy of anti-angiogenic 
therapy, possibly improving also the benefits of vascular normalization (Figure. 7). 
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Figure 7. Mechanisms of neovascularization. 
Tumors vessels form by several mechanisms including sprouting angiogenesis, vessel co-
option between tumor and endothelial cells, vasculogenic mimicry and intussusceptive 
angiogenesis. In these processes not only ECs are involved but also several other cell types 
such as pericytes, bone-marrow derived cells and tumor cells. A novel therapeutic 
approach able to hit several targets and different cell types concomitantly might increase 
the benefit of current anti-angiogenic therapy and vascular normalization (Adapted from 
Bingxue Shang et al. 2012, 40). 
 
 
Finally, new targets should be identified, an objective that can only be achieved through a 
deeper understanding of the molecular players and mechanisms that operate within the 
tumor vasculature. In this context, the results obtained by our group on the novel role of 
the adhesion molecule L1 in tumor-associated vasculature 41, as described later in the 
introduction, provides a strong rationale for exploring this molecule as a new target. 
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1. 1. 5 Novel anti-angiogenic targets: the perivascular niches of cancer stem 
cells. 
In the last years, several studies demonstrated a pivotal role of cancer stem cells (CSCs) in 
promoting tumor growth and metastasis 42 . CSCs consist of a rare cell population within 
the tumor mass and are multipotent, self-renewing and capable of generating the entire 
variety of cell types present in a tumor 43. Importantly, CSCs are often quiescent and 
therefore may not be affected by therapies targeting rapidly dividing cells. Moreover, 
CSCs usually express transporters that pump out chemotherapeutic agents 44 and posses an 
increased capacity to repair DNA damage 45, allowing them to survive to conventional 
chemotherapy. These peculiar characteristics may help explaining why such therapies 
often fail in clinics: although they are able to destroy the tumor bulk, they cannot prevent 
the surviving of CSCs, thus accounting for metastasis and relapse 46. 
Another peculiar characteristic of CSCs is that they are usually found in a specialized 
microenvironment called “niches” which provide CSCs with survival and proliferation-
promoting factors. In some tumor types, such as head and neck squamous cell carcinomas 
47 and brain tumors 48, CSCs reside in perivascular niches where the existence of a cross-
talk between CSCs and endothelial cells is crucial for their survival 47. Moreover, the 
perivascular niche can also protect CSCs from chemotherapy, thus enhancing the 
probability of tumor relapse.  
These discoveries open novel therapeutic option for CSC-driven tumors (such as ovarian 
cancer, as discussed below). Moreover, the pharmacological blockade of the cross-talk 
between ECs and CSCs within the perivascular niche may represent a novel therapeutic 
opportunity for cancer patients. In this context, anti-angiogenic drugs may have a double 
therapeutic effect: they can target both ECs and their cross-talk with CSCs, thus preventing 
not only the formation of new tumor-associated vessels but also ablating the fraction of 
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self-renewing cells within the tumors, resulting in the repression of tumor growth 49 
(Figure. 8). 
 
 
 
Figure 8. The perivascular niche of cancer stem cells: a novel target for anti-angiogenic 
therapy.  
CSCs reside in niches in close proximity with blood vessels and continuously receive 
survival signal from these specialized microenvironment (A) CSCs undergo self-renewal to 
maintain the CSCs pool but are also able to generate transit-amplifying cells that 
proliferate while acquiring a differentiated phenotype. The unceasing onset of 
differentiated tumor cells foster tumor growth. (B) The anti-angiogenic therapy targeting 
blood vessels might disrupt the CSCs niche, blocking the cross-talk between blood vessels 
and CSCs. The CSC pool might be exhausted (Adapted from Zeng-Jie Yang & Robert J. 
Wechsler-Reya 2011, 49). 
 
 
1. 2 Ovarian cancer: cancer types and cell of origin  
 
Ovarian cancer (OC) is the second most common and the most lethal gynecological 
malignancy in developed countries. No specific symptoms are associated to the early phase 
of the disease and, therefore, the majority of OC is already at advanced stage at the time of 
diagnosis, with massive peritoneal spread of tumor as well as ascitic fluid 50. 
Based on a series of morphologic and molecular genetic studies, Shih and Kurman 
proposed a dualistic model to classify ovarian carcinomas into type I and type II tumors 51. 
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Type I tumors include low-grade serous carcinoma, low-grade endometrioid, clear cell and 
mucinous carcinoma. These tumors are usually diagnosed at early stage, in most cases they 
grow slowly and are not clinically aggressive. At the molecular level, type I tumors are 
characterized by mutation in KRAS, BRAF, PTEN, PIK3CA and BCL2. Type II OCs, 
instead, are mostly represented by high-grade serous carcinoma but include also high-
grade endometrioid carcinomas, carcinosarcomas and undifferentiated carcinomas. They 
are highly aggressive and usually exhibit TP53 mutation and high genomic instability 52,53.  
The ovarian surface epithelium (OSE), which is a layer of simple squamous-to-cuboidal 
epithelial cells covering the ovary, has long been thought to be the unique source of OC 
(Figure. 9A and 9B). 
In 1971 Fathalla formulated the “incessant ovulation hypothesis” 54 where he stated a 
possible relationship between the repeated involvements of the ovarian surface epithelium 
in the process of ovulation and the development of the epithelial OC 54. Indeed, every 
ovulation induces a wound in the OSE that must be repaired by postovulation mitosis and 
cell proliferation mechanisms, thus increasing the probability of alterations in the DNA 
repair mechanisms and the selection of putative carcinogenic mutations 55. Over the time, 
this model has expanded and mediators of inflammation and hormones have been 
described as carcinogenesis-promoting factors. Indeed, with the release of an oocyte with 
its adherent cumulus granulosa cells into the adjacent fallopian tube, both the ovarian 
surface and the tubal fimbria are bathed with follicular fluid abundant of inflammatory 
cytokines, reactive oxygen species, and steroids 56,57. Furthermore, due to the cyclic 
ovulation-induced rupture, the OSE was supposed to invaginate into the underlying stroma 
thus forming inclusion cysts. Subsequently, metaplastic changes would promote the 
acquisition of a “müllerian phenotype” by epithelial cells 58, thus leading to the 
development of the different cell types, which morphologically resemble the epithelia of 
the fallopian tube in high-grade serous OC, the endometrial epithelium in endometrioid 
OC, and the gastrointestinal tract or endocervix epithelium in mucinous OC (Figure. 9B). 
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However, the normal ovary does not have any cellular components would act as precursors 
of those tumor cell types. In fact, while cervix, endometrium and fallopian tubes derive 
from the müllerian ducts, the ovaries develop from mesodermal epithelium of the 
urogenital ridge 52,59. Therefore, a more recent theory proposes the distal portion of the 
fallopian tube, that is the fimbriae epithelium, as an alternative source of OC cells (Figure. 
9A and 9C). The first evidence in favor of such a theory came from the pathological 
examination of the fallopian tubes derived from prophylactic salpingo-oophorectomies 
carried out in high-risk OC patients. A meticulous sectioning of the entire tube led the to 
the discovery of foci of in situ tubal intraepithelial carcinoma (TIC) 53,60,61. It was then 
hypothesized that malignant cells shed from the occult tubal carcinoma onto the ovaries 
where they can implant and form a tumor mass, which resembles a primary ovarian 
carcinoma. Moreover, tumor cells can also directly colonize the abdominal cavity from the 
tube, thus explaining the recurring peritoneal dissemination of high-grade OC and the 
presence of ascitic fluid in patients at the time of diagnosis.  
 
 
Figure 9. Possible origins of ovarian cancer cells. 	  
A) Organization and anatomy of the adult human ovary and the fallopian tube. The ovary 
and the fimbriae are anatomically contiguous. The ovary is lined by a monolayer of 
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ovarian surface epithelium (OSE). The adult fimbrial epithelium comprises two epithelial 
cell types: ciliated cells and secretory cells. B) Derivation of OC from OSE. OSE 
invaginates and forms an inclusion cyst. Due to metaplastic changes, ephithelial cells 
might become neoplastic and form a tumor mass in the ovary. C) Derivation of OC from 
fimbriae ephithelium. An in situ intra-ephithelial carcinoma (STIC) might develop in the 
fimbriae and, thereafter, transformed cells can be released onto the ovary and generate a 
tumor mass (Adapted from Annie Ng and Nick Barker 2015 62 ). 	  
 
1. 2. 1 Epithelial-mesenchymal transition and stem cells in ovarian cancer  
 
Debulking surgery followed by platinum/taxane therapy is the standard treatment for 
advanced ovarian cancer patients. Despite most patients show a good response to the 
chemotherapy, 60% to 80% of women with advanced OC eventually relapse and develop 
drug-resistant disease. OC patients typically survive only for 16-21 months, succumbing to 
metastatic spread of the disease.  
Although the mechanisms of OC chemoresistance are still poorly understood, several 
studies have implicated the epithelial-mesenchymal (EMT) transition and cancer stem cells 
(CSCs) in the development of resistance to therapy and the consequent tumor relapse and 
metastasis 63. Moreover, the two biological phenomena appear to be intimately connected, 
as EMT not only is a frequent hallmark of CSCs, but it has been shown to be causally 
involved in the acquisition of CSC traits 42,64.  
EMT is a biological reversible process by which epithelial cells acquire mesenchymal 
properties, such as migratory activity. During embryogenesis, epithelial cells acquire 
mesenchymal markers to migrate through the extracellular environment and colonize other 
organs, giving rise to endoderm, esoderm and mobile neural crest cells. In cancer, instead, 
EMT is associated with the acquisition of an invasive phenotype by cancer cells and their 
ability to disseminate from the primary mass, by regulating the production of matrix 
metalloproteases and altering the cytoskeletal organization 63. At the molecular level, EMT 
occurs through the up-regulation of several EMT-inducing transcriptional factors (EMT-
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TFs) such as Snail1, Snail2, Zeb1, Zeb2, Twist, Klf8, and the modulation of adhesion 
molecules and cytoskeletal components, including N-cadherin, E-cadherin, Cytokeratins, 
Claudins and Occludin 42,65. 
Several studies have demonstrated a pivotal role of EMT in acquired invasiveness and 
metastatic potential of OC cells. Takai and colleagues analyzed 174 primary tumors and 34 
metastases of OC by immunohistochemistry. They showed that the reduction in E-cadherin 
expression together with the up-regulation of Snail correlated with more peritoneal 
metastasis and decreased PFS and OS in OC patients 66. Moreover, several studies in OC 
cell lines demonstrated that the exposure of OC cells to chemotherapeutic agents induced 
EMT and chemoresistance 67,68. The correlation between acquired chemoresistance and the 
expression of EMT markers have also been confirmed in primary OC samples. Indeed, 
Davidson et al identified a panel of EMT- and CSC-related genes as markers of poor 
chemoresponse in metastatic serous OC effusion 69. 
In addition to EMT process, accumulating evidence indicates that the existence of a small 
population of CSCs within the tumor mass is intimately correlated with OC progression, 
chemoresistance and tumor relapse 42. A variety of strategies have been tested to identify 
and isolate OCSCs from OC cell lines and primary samples 70-73. A number of cell surface 
markers have been proposed to isolate subpopulations of cells enriched for OCSCs.  
CD133 glycoprotein has emerged as one of the most promising CSC marker in EOC. 
CD133+ cells showed an increased tumorigenic potential as compared with CD133- 
counterpart in immunocompromised mice and they possessed an increased resistance to 
platinum-based therapy in vitro 70. In addition, CD133 expression correlated also with 
decreased response to chemotherapy 74. However, the results obtained using CD133 as a 
putative marker of CSCs are conflicting. Indeed, Kusumbe and coworkers demonstrated 
that CD133-expressing ovarian cancer cells are not tumorigenic per se but they augmented 
tumor development and progression by contributing to the development of tumor 
vasculature 75. 
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Other groups have proposed aldehyde dehydrogenases (ALDHs), a family of NADP-
dependent enzymes that catalyze the oxidation of a broad spectrum of aldehydes, as 
promising markers for the isolation of OCSCs. Landen et al isolated for the first time 
ALDH+ OCSC and showed that high level of ALDH activity correlated with poor outcome 
in OC patients 72. Moreover, in 2011 Silva et al demonstrated that few ALDH/CD133 
double positive OCSC isolated from human tumor possessed tumor initiation capability in 
mice and that their presence in primary OC samples correlated with reduced disease-free 
survival (DFS) and OS 76.  
In spite of the significant efforts devoted to the identification of strategy and markers to 
identify, isolate and target OCSCs, the results obtained so far are mostly inconsistent and 
unequivocal markers of OCSC are still missing. A deeper understanding of the biology of 
EMT and CSC in the development of OC and in its response to therapy may direct tumor 
research towards novel EMT/CSC targets, hopefully leading to innovative targeted 
therapy.  
 
1. 2. 2 Anti-angiogenic drugs in ovarian cancer 
The current standard of frontline therapy for OC patients is represented by combination 
surgery and cytotoxic chemotherapy. However, the approval of Bevacizumab in 2004 for 
the treatments of cancer patients had represented a novel therapeutic opportunity also for 
OC patients. In gynecological cancer, four phase-III clinical trials have been performed: 
the Gynecologic Oncology Group 218 (GOG-218) and the Gynecologic Cancer InterGroup 
International Collaboration on Ovarian Neoplasms 7 (GCIG ICON7) in first-line setting, 
and the OCEANS and AURELIA in recurrent setting 77.  
The GOG-218 trial enrolled 1873 women with previously untreated stage III or stage IV 
epithelial ovarian cancer, primary peritoneal or fallopian tube carcinoma. It was a three 
arms trial where patients received carboplatin and paclitaxel (CT) together with 
concomitant and maintenance placebo (control group), or concomitant Bevacizumab and 
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maintenance placebo (the Bevacizumab-initiation group), or concomitant and maintenance 
Bevacizumab (the initiation-throughout group). This study showed an increase in the 
progression free survival (PSF) from 10.6 months in control group to 11.2 months in the 
Bevacizumab-initiation group and to 14.1 months in the initiation-throughout group 77. 
The two-arm trial GCIG ICON7 enrolled 1528 women with high-risk early-stage and 
advanced epithelial OC, primary peritoneal or fallopian tube carcinoma. Patients were 
treated with CT with/without concurrent and maintenance Bevacizumab. Also in this study 
the addition of Bevacizumab to the standard therapy increased the PFS of OC patients 
from 20.3 to 21.8 months.  
In recurrent setting, instead, the OCEANS trial enrolled 484 patients with platinum-
sensitive OC. Patients were randomized to gentamicine and carboplatinum plus either 
placebo or Bevacizumab. The addition of the anti-angiogenic drug to chemotherapy 
increased the median PFS from 8.4 to 12.4 months. In the AURELIA trail, 361 women 
with platinum-resistant OC were randomized to six arms: paclitaxel, topotecan, liposomal 
doxorubicin with or without Becacizumab. The addition of Bevacizumab to chemotherapy 
double the median PFS.  
Another anti-angiogenic therapeutic opportunity for OC patient could be represented by 
the VEGF receptor tyrosine kinase inhibitors, such as Cediranib 78 and Pazopanib 79. These 
small molecule inhibitors gave some same clinical benefits in terms of improved PFS even 
if with noted side effects. However, in none of these trials the addition of the anti-
angiogenic drug to CT did induce an increase in OS since the vast majority of OC patients 
became unresponsive to anti-angiogenic therapy shortly after the initiation of the therapy.  
 
In addition to reduced neovascularization and tumor burden, in preclinical models anti-
VEGF drugs seem to reduce the amount of ascitic fluid in the abdominal cavity, a well 
known hallmark of late-stage OC 80. The massive accumulation of peritoneal ascites is due 
to the obstruction of lymphatic vessels by tumor masses and the increased leakiness of 
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tumor microvasculature 81. The ascitic fluid also acts as a reservoir for growth factors, 
cytokines and chemokines, that foster OC growth by inducing cancer cell proliferation and 
tumor angiogenesis, and by preventing immunosurveillance 82. The current treatment of 
malignant ascites is represented by standard chemotherapy. Once the tumor becomes 
resistant to therapy and relapses, the majority of patients undergo paracentesis procedure to 
alleviate ascites-related symptoms such as abdominal pain. VEGF-based anti-angiogenic 
drug gave encouraging results also in clinical setting. Indeed, the use of Bevacizumab 
promoted symptomatic relief of ascites 83,84. However, in all patients ascites reformed after 
few months. Moreover, no randomized trials using Bevacizumab specifically for the 
elimination of ascites have yet been reported. 
Another encouraging result came from a phase-II clinical trials using the VEGF-trap 
aflibercept, a drug that is able to bind VEGF and placental growth factor (PlGF). It 
significantly prolonged the median time to paracentesis 85, yet with high morbidity. Even 
though the contribution of current angiogenic-drug for the eradication of ascites is unclear 
and unsatisfactory 86,87 , tumor angiogenesis and the high permeability of tumor 
vasculature seem intimately linked to the ascites formation. Thus, the anti-angiogenic 
therapy might represent a promising strategy to manage ascites formation and its related 
symptoms in OC patients.  
 
Overall, in order to improve the clinical benefits derived from the addition of anti-
angiogenic drug to chemotherapy for the treatment of OC, it has to be taken into account 
that OC is a highly heterogeneous disease. Indeed, epithelial ovarian cancers are classified 
into five main immunohistological subtypes that differ in term of chemosensitivity, overall 
survival and driver genetic mutations. Despite these differences, the vast majority of 
clinical trials have been performed in unselected cohort of patients. Future strategies to 
design the suitable patient population to be treated with a defined drug, together with the 
identification of additional molecular pathways, could offer novel therapeutic opportunities 
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to overcome these limitations, especially for a tumor with high mortality rate such as OC 
88. 
 
1. 3 The cell adhesion molecule L1: a novel player in tumor-associated 
vasculature 
L1-cell adhesion molecule (L1CAM or L1) is a 200-220 KDa transmembrane protein that 
belongs to the immunoglobulin superfamily 89. It is composed by an extracellular portion, 
which contains six Ig-like domains and five fibronectin type III repeats (FNIII-like), a 
transmembrane region and a short cytoplasmic tail 89 (Figure. 10). L1 is involved in 
homophilic and heterophilic interactions on the cell surface. Partners of L1 heterophilic 
interactions include integrins and receptor tyrosine kinases (RTKs), such as fibroblast 
growth factor receptor (FGFR). These interactions have functional implications, for 
example modulating cell motility and signal transduction 90.  
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Figure 10. L1 structure 
L1 cell adhesion molecule belongs to immunoglobulin super-family. It is composed by six 
Ig-like domains (purple), five fibronectin type-III repeats (FNIII domain, yellow), a 
transmembrane region and a conserved cytoplasmic tail (blue) (Adapted from Chun Hua 
Wei & Seong Eon Ryu 2012, 91). 
 
L1 can undergo membrane-proximal cleavage by a disintegrin and metalloproteinases 
(ADAMs), which generates a soluble 200-kDa ectodomain and a membrane-retained stub 
of 32 kDa 92. The shedding of the ectodomain occurs at the surface of normal and tumor 
cells but also in cell-derived vesicles, called exosomes 93. Moreover the soluble 
ectodomain of L1 is biologically active: it promotes cell migration 94, protects cell from 
apoptosis 95 and stimulates angiogenesis 96. The membrane-retained cytoplasmic tail is a 
substrate of γ-secretase, which, upon cleavage of the intra-membrane portion, releases a 
soluble L1 intracellular domain that is able to translocate into the nucleus and regulate 
gene transcription 97 (Figure. 11). 
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Figure 11. L1 processing at the plasma membrane. 
At plasma membrane L1 undergoes to proteolytic cleavage of the extracellular domain 
that results in the shedding of the extracellular portion of the protein. The membrane-
retained intracellular tail is further processed by g-secretase. This second cleavage results 
in the formation of a soluble cytoplasmic tail that is able to translocate from the cytoplasm 
to the nucleus where it regulates gene transcription (Adapted from Cavallaro U & Dejana 
E. 2011, 98). 
 
L1 was initially characterized as an adhesion molecule playing a key role in the 
development of nervous system 99. Thereafter, several studies reported the expression of 
L1 in different cell types, such as immune cells 100 and tumor cells 101. Indeed, it was 
demonstrated that the aberrant expression of L1 in various cancer types, including 
endometrial carcinoma, pancreatic ductal carcinoma, melanoma and glioblastoma, 
correlates with tumor malignancy and poor prognosis 97. 
In OC, the expression of L1 is frequently increased in high-grade serous tumor while it is 
absent in the normal counterpart 93, and its expression correlates with the risk for 
suboptimal debulking 102. In OC patients, soluble L1 can also be detected in serum and 
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ascitic fluid 93, and the expression of L1 in tumor cells correlates with higher level of 
soluble L1 released in the ascitic fluid, which might imply a functional role of the 
ectodomain fragment in OC. Of note, L1 shedding represents an unfavorable indicator for 
OC response to chemotherapy and patient survival 93,102. 
Several studies demonstrated a role of L1 in various cellular processes related to 
tumorigenesis such as invasiveness and migration 97, thus supporting the metastatic spread, 
as well as chemoresistance. Accordingly, inhibition of L1 by RNA interference or 
antibody-mediated blockade reduced migration and proliferation of ovarian tumor cells in 
vitro 95,103,104. Furthermore, treatment of OC mouse models with L1-neutralizing antibodies 
reduced tumor burden and decreased ascites volume 105,106. Finally, the combined treatment 
of OC-bearing mice with L1 antibody and paclitaxel improved the therapeutic response 107.  
Within a tumor, the neoplastic cells are by no means the only cell type where L1 can be 
found. Indeed, our group has analyzed a wide range of solid tumors and showed that L1 is 
commonly expressed in the cancer-associated vasculature, while it is almost absent in 
normal vessels 100. Besides confirming previous scattered reports on the expression of L1 
in tumor vasculature of breast, ovarian, colon and pancreatic carcinoma 100,108, these results 
point to L1 as a potential marker of pathological angiogenesis. Furthermore, by combining 
genetically manipulated mouse tumor models with in vitro endothelial cell biology studies, 
we have recently discovered a novel, pleiotropic role of L1 in tumor vasculature, which 
implicates this molecule in cancer neovascularization and in the dysregulation of cancer 
vessel integrity and function (See background and rationale) 41. 
Overall, the cell surface localization of L1 together with its specific upregulation in tumor-
associated vasculature, make it a possible marker of advanced stage cancer as well as a 
potential candidate for novel anti-angiogenic therapy to fight incurable and aggressive 
human tumors, such as OC. 
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2. MATERIALS & METHODS 	  
2. 1 Cell lines 
Mouse lung-derived ECs (luECs), were immortalized with polyoma middle T antigen as 
previously described 109 and cultured in MCDB131 medium (Gibco) supplemented with 
20% North American (NA) Fetal Bovine Serum (FBS) (Invitrogen), 2 mM L-Glutamine 
(Lonza), 1 mM Na-pyruvate (Gibco), 100 µg/ml heparin (Sigma), 50 µg/ml EC growth 
supplement (ECGS) obtained from calf brain. ECs were seeded on 0.1% gelatin (Sigma) 
and cultured at 37°C in humidified atmosphere with 5% CO2. Where indicated, EC 
adhesion was enhanced by coating tissue culture plates with glutaraldehyde–crosslinked 
gelatin, as follows. Plates were incubated overnight with 1% gelatin at 37°C followed by a 
crosslinking with 2% glutaraldehyde for 15 minutes at room temperature (RT). 
Glutaraldehyde was replaced with 70% ethanol for 1 hour at RT. After 5 washes with PBS 
(Lonza), plates were incubated for 2 hours at 37°C with 2 mM glycine in PBS (Lonza). 
Prior to cell seeding, plates were washed 5 times with PBS (Lonza). 
luECs expressing full length murine L1 (luEC-L1) and the control cells (luEC-mock) were 
obtained as previously described 41. 
ID8 cells, a spontaneously transformed mouse ovarian cancer cell line, were cultured in 
DMEM (Lonza), 5% FBS (Invitrogen), 2mM L-Glutamine (Lonza). 
B16-F10 melanoma cell line, was cultured in DMEM (Lonza), 10% FBS (Invitrogen), 
2mM L-Glutamine (Lonza). 
HEK293 cells were cultured in DMEM (Lonza), 10% FBS (Invitrogen), 2mM L-
Glutamine (Lonza). 
 
2. 2 Mice 
L1floxed and Tie2-Cre mice were generated in the C57BL/6 genetic background as 
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previously described 100. To obtain Tie2-Cre; L1fl/ fl females, L1fl/fl females were crossed 
with Tie2-Cre;L1fl male mice. Genomic DNA of the offspring was isolated from tail 
biopsies and the genotype was determined by PCR analysis for Tie2 gene (see below). 
NOD/SCID/IL2Rgnull female mice were purchased from Charles River Laboratories. 
2. 3 Mouse genotyping 
Tail tips were washed in Ethanol 100% and in PBS (Lonza) and then digested in Digestion 
Buffer (16.6 mM Ammonium Sulfate, 0.5 mM ß- 2-mercaptoethanol, 0.05 M EDTA pH8, 
0.15 M Tris-HCl pH 8.8, 570 ug/mL Proteinase-K (Sigma), 10% Triton-X100 in water) 
shaking, overnight at 55 °C. Proteinase-K was inactivated by high temperature (95°C, 20 
minutes).  
Digested tails were centrifuged at 12,000 g for 5 minutes at RT and 2 µL of supernatant 
was used for the PCR analysis for the Tie2 promoter.  
Primer forward: CCAAAATTTGCCTGCATTACCGGTCGATGC;  
Primer reverse: ATCCAGGTTACGGATATAGT. 
 
2. 4 In vivo models 	  
2. 4. 1 Syngeneic mouse model of ovarian cancer 
The syngeneic mouse model of ovarian cancer has been described previously 110. Briefly, 
one million of ID8 ovarian carcinoma cells stably expressing GFP were injected intra-
peritoneally into 8-10 week old female mice. One month after the injection, animals were 
sacrificed and tumor dissemination into the abdominal cavity was measured by fluorescent 
stereomicroscope. In particular, the abdominal wall, omentum and diaphragm were 
analyzed by stereomicroscopy for GFP-positive implants. For each organs, picture of GFP-
positive implants were taken. The number of tumor implants was counted as described in 
paragraph 2. 5). Then, all the organs were embedded in Killik cryostat embedding medium 
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(Bio-Optica 05-9801) and stored at -80 °C for ex-vivo analysis.  
 
2. 4. 2 CO-transplantation of ID8 cells and luECs  
GFP-expressing ID8 cells were mixed with luEC-L1 or luEC-mock (two ratios tested, 
1x106:1x106 or 5x105:1x15) and were transplanted subcutaneously in 8-10 week old 
NOD/SCID/IL2Rgnull female mice in a final volume of 160 uL (1:1 with Matrigel, Cat. 
356231, Corning). When tumors reached the size of 450 mm3, animals were sacrificed and 
tumors were digested in Digestion Buffer (HAM’s F12+DMEM 2mM L-Glutamine, 
200U/mL Collagenase IA and 100 U/mL Hyaluronidase) for 2 hours at 37°C in order to 
obtain a single cell suspension. GFP-expressing ID8 cells were then isolated from digested 
tumors by FACS sorting (BD Influx Cell Sorter 646500). 2x104 cells were re-transplanted 
subcutaneously into 8-10 week old NOD/SCID/IL2Rgnull female mice. Tumor growth was 
assessed two times per week by caliper measurements. Tumor volumes were recorded at 
the indicated time points and calculated using the formula V = (d*d*D/2), where d and D 
are the minor and the major tumor axis, respectively. 
 
2. 4. 3 CO-transplantation of ID8 cells and conditioned medium (CM) derived 
from endothelial cells  
Conditioned medium derived from luEC-L1 (luEC-L1-derived CM) and from luEC-mock 
(luEC-mock-derived CM) was prepared in MCDB 131 medium (Gibco) without serum, it 
was collected after 48-60 hours of culture and was centrifuged at maximal speed for 10 
minutes. 106 GFP-expressing ID8 cells were transplanted subcutaneously in 
NOD/SCID/IL2Rgnull female mice (8-10 week old female mice) together with 50 µl of 
luEC-L1-derived CM or luEC-mock-derived CM and 50 µl Matrigel Matrix (Cat. 356231, 
Corning). Tumor growth was assessed one time per week by caliper measurements. 
Tumors volumes were recorded at the indicated time points and calculated as reported 
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above.  
2. 5 Quantitation of tumor implants  
In order to quantify GFP-expressing ID8-derived tumor implants in an unbiased way, we 
adopted the “Otsu Method” (IEEE TRANSACTIONS ON SYSTEMS, MAN, AND 
CYBERNETICS, VOL. SMC-9, No.1, JANI'ARY 1979), which is an algorithm used to 
automatically perform image thresholding. Any image is composed by pixels with 
different intensity values, ranging from 0 to 255 (for 8-bit images). This method allows 
stratifying all pixels into two levels: a foreground (GFP-signal) and a background. 
The Otsu method calculates the optimal threshold able to separate the foreground and the 
background so that their intra-class variance is maximal. For each organ, the best threshold 
was determined and then the number of GFP-expressing tumor implants was counted using 
a custom-made macro of ImageJ software. This macro identifies the GFP-positive lesions 
in each organ and counts them. The final output of this analysis is the number of tumor 
implants per organ. 
 
2. 6 Cell migration assay  
To assess cell migration, we employed the wound-healing assay. luECs were seeded on 
fibronectin-coated (1 µg/cm2) 24-well plates. Confluent monolayers of luECs were starved 
for 24 hours in MCDB131 medium (Gibco) containing 0.5% FBS. Monolayers were 
wounded with a plastic pipette tip to induce EC migration into the wound. Where 
indicated, cells were treated for 2 hours with 100 nM FGFR inhibitor PD173074 or vehicle 
only (DMSO). Images of the wounds were acquired at 0 and 24 hours. The width of the 
wounds was measured with ImageJ software, and the distance covered by luECs, 
expressed as µm in 24 hours, was calculated according to this formula: (wound width at 0 
– wound width at 24 hours). 
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2. 7 Cell proliferation assay  
ECs were seeded at a density of 2x103 cells/well in 96-well plates coated with 
glutaraldehyde–crosslinked gelatin. After overnight incubation in medium containing 5% 
FBS, cells were stimulated with medium containing 20% FBS, 100 µg/ml heparin, and 50 
µg/ml ECGS. Where indicated, cells were treated with 100 nM FGFR inhibitor PD173074 
or vehicle only (DMSO). Cells were fixed at 0, 24, 48, and 72 hours, followed by staining 
with 0.1% crystal violet in 20% methanol. Bound dye was solubilized with 10% acetic 
acid, and the absorbance at 590 nm was measured. Cell growth was normalized on 
absorbance measured at 0 hours.  
 
2. 8 Tube formation assay 
Matrigel-based tubulogenesis assay was performed to assess the ability of ECs to form 
capillary-like structures. Confluent ECs were starved overnight with medium containing 
1% FBS. Growth factor-reduced Matrigel was thawed overnight at 4°C on ice and, the day 
of the assay, 50 uL of Matrigel were plated on the bottom of 96-well plate and left at 37°C 
for 1 hour for gelification. Thereafter, 1x104 cell/well were seeded on Matrigel and 
incubated at 37 °C. Optical images of the wells were acquired after 7 hours at 4X 
magnification using EVOS FL Imaging System. The tubes in each well were manually 
counted. The experiments were performed in triplicates and repeated three times. 
 
2. 9 Antibodies 
The following antibodies were used as indicated:  
Mouse anti-human L1 (clone UJ127; 1:30 in IHC on human tissues; Thermo Scientific); 
Purified anti–mouse CD31 (clone MEC 13.3; 1:50 in IF on mouse tissues, Santa Cruz); 
Rabbit anti-mouse L1 728 (polyclonal antibody against mouse L1-Fc produced in our lab, 
41); 
Rat anti IL-6 antibody (Clone MP5-20F3; Cat. 504506, BioLegend); 
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IgG from rat serum  (I4131, Sigma). 
Secondary antibodies for immunofluorescence analyses: Cy3-conjugated donkey anti-
rabbit (Li-Starfish, 1:500); Cy5-conjugated donkey anti-rat (Li-Starfish, 1:500). 
Secondary antibodies for immunoblot analysis: HRP-linked goat anti-rabbit (1:3000, 
BioRad). 
 
2. 10 Immunoprecipitation  
LuEC-L1- and luEC-mock-derived CM was prepared as described in paragraph 2. 4. 3. 
2 mL of CM was added with 30 µL of rec-Protein G-sepharose 4B Conjugate (10-1242, 
Invitrogen) and 5 µg of rat IgG for medium pre-clearing and leaved 1 hour at 4°C under 
rotation. At the end of the incubation, medium was centrifuged at maximal speed for 1 
minute and it was divided in two parts. 1 mL of medium was incubated with 3.3 µg of rat 
anti IL-6 antibody for 2 hours at 4°C under rotation and 1 mL with 3.3 µg of rat IgG, as 
control. 
Therefore, 20 µL of rec-Protein G-sepharose 4B Conjugate (10-1242, Invitrogen) was 
added and samples were left 2 hours at 4°C under rotation.  
The IL6-depleted medium was used for the sphere assay (See section 2.18). 
 
2. 11 Immunoblotting  
Proteins were extracted from ID8 and B16-F10 cells using RIPA lysis buffer (0.1% SDS, 
0.5% DOC, 1% TritonX-100, 150mM NaCl, 50 mM Tris pH 7.4). Cell extracts were 
sonicated and then centrifuged for 5 minutes at 12,000 g to discard cell debris. The 
supernatants were collected, and the concentration of protein was determined using Bio-
Rad Protein Assay Dye Reagent Concentrate (Cat. 500-0006, Bio-Rad) according to the 
manufacturer’s instructions. 25 ug of protein were separated on SDS polyacrylamide gel 
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(SDS-PAGE) and blotted on nitrocellulose membranes using Trans-Blot Turbo Transfer 
Pack (BIO-RAD). Membranes were incubated in blocking solution (TBS, 0.1% Tween 20 
containing 5% nonfat milk) for 2 hour at RT and then overnight at 4°C with primary 
antibodies diluted in blocking solution. Membranes were then incubated with horseradish 
peroxidase–conjugated secondary antibodies (BIO-RAD) and the signal was detected by 
the Clarity Western ECL Substrate (BIO-RAD) and acquired using Chemidoc (Universal 
hood II, Bio-rad). 
 
2. 12 Immunofluorescence 
 
ID8 tumors were embedded in Killik cryostat embedding medium (Bio-Optica 05-9801). 
Tumor sections (3 µm) were fixed 10 minutes in 4% paraformaldehyde (PFA) and 
incubated for 1 hour at RT with a blocking solution (PBS (Lonza), 2% bovine serum 
albumin (BSA), 5% donkey serum, and 0.05% Triton X-100). Samples were then 
incubated 2 hours with primary antibody diluted in blocking buffer, followed by the 
incubation with secondary antibody (45 minutes at RT). Samples were then washed in PBS 
and counterstained with DAPI solution. 
2. 13 Immunohystochemistry 
The immunohistochemical analysis of L1 expression was carried out on different normal 
samples and high-grade serous ovarian carcinoma. Samples were 4% PFA-fixed and 
paraffin embedded. After an over-night at 37 °C, tumor sections (3 µm) were 
deparaffinized using Leica ST5020 Multistainer according to the following protocol: 
bioclear (Bio-Optica Ref. 06-1782D) 15 minutes for two times, Absolute Ethanol 5 
minutes for two times, 95% Ethanol 5 minutes, 70% Ethanol 5 minutes, 2 washes of 2 
minutes in distilled water. According to the primary antibody used, tissue sections were 
treated with the antigen unmasking solution EDTA pH 8 in pre-wormed water bath a 95 °C 
for 50 minutes. After two washes in water, endogenous peroxidases were blocked using 
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3% Hydrogen peroxide solution (Carlo Erba, 412072). Tissue sections were incubated with 
the blocking solution (TBS, 2% BSA, 2% normal goat serum (ECS0200D/L, EuroClone), 
and 0.05% Triton X-100) for 1 hour. Samples were then incubated 2 hours with primary 
antibodies diluted in blocking buffer, followed by secondary antibodies (Dako EnVision+ 
System-HRP Labelled Polymer) for 30 minutes at RT. Dako chromogen substrate (Liquid 
DAB+ Substrate Chromogen System Ref. K3468) was used for signal detection. Samples 
were then washed and counterstained using Hematoxylin solution (Leica). Pictures of 
stained sections were acquired with the scanner Aperio ScanScope XT, 20x objective. 
 
2. 14 H&E staining  
Hemangioma sections were 4% PFA-fixed and paraffin embedded. After an overnight at 
37 °C, tumor sections (3 µm) were deparaffinized using Leica ST5020 Multistainer 
according to the following protocol: bio-clear (Bio-Optica Ref. 06-1782D) 5 minutes for 
two times, absolute ethanol for 2 minutes for two times, 95% ethanol for 2 minutes, 70% 
ethanol 2 minutes. After two washes of 2 minutes in distilled water, tissue sections were 
then treated with hemalast reagent (Leica) for 30 seconds and with Hematoxylin (Leica) 
for 5 minutes. After one wash in water, sections were treated with differentiator solution 
(Leica) for 45 seconds. After one wash in water, sections were treated with bluing agent 
(Leica), treated with ethanol 80% for 1 minute and finally stained with eosin (Leica) for 1 
minute. Hemalast, Hematoxylin, differentiator, eosin and bluing reagents were from Leica 
ST Infinity H&E Staining System (Leica, 3801698). 
 
2. 15 Gene Expression profiling 
ECs were seeded on plates coated with glutaraldehyde–crosslinked gelatin and cultured in 
complete medium for 4 days to reach confluence. Cells were treated with FGFR inhibitor 
PD173074 or DMSO for 2 hours and then total RNA was extracted with RNeasy Mini Kit 
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(QIAGEN). Quality control of the RNA samples was performed using Agilent Bioanalyzer 
2100 (Agilent Technologies). Two different RNA extractions were processed for each 
condition. Each sample was labeled and hybridized to a Mouse Gene 1.0 ST Genechip 
array according to the manufacturer’s instructions (Affymetrix). Data were normalized 
using the Robust Multi-array Average (RMA). 
 
2. 16 RNA extraction from ID8 cells or luECs and quantitative RT-PCR 
analysis 
ID8 cells, B16-F10 cells or luECs were cultured as described above. Total RNA was 
isolated by extraction with RNeasy Mini Kit (QIAGEN). 2 µg or RNA were reverse-
transcribed with random hexamers (SuperScript ViloTM cDNA Synthesis Kit; Invitrogen) 
according to manifacturer’s instructions. cDNA samples (5 ng) were amplified in triplicate 
with the TaqMan 710 Gene Expression Assay (Applied Biosystems) and an ABI/Prism 
7900 HT thermocycler (Applied Biosystems). Preparations of RNA template without 
reverse transcriptase were used as negative controls.  
For qRT-PCR analysis performed on ID8 and B16-F10 cell lines, gene expression level 
was normalized against the geometric mean of the housekeeping genes encoding for 
GAPDH and 18S. 
For qRT-PCR analysis performed on luECs, gene expression level was normalized against 
the geometric mean of the housekeeping genes encoding for GAPDH and ACTB.  
 
2. 17 RNA extraction from paraffin embedded tumors  
Total RNA was extracted from 2 sections of 10 µm derived from paraffin embedded ID8- 
tumors following the Manufactory’s protocol (AllPrep DNA/RNA FFPE, Qiagen). 2 µg or 
RNA were reverse-transcribed with random hexamers (SuperScript ViloTM cDNA 
Synthesis Kit; Invitrogen) according to manifacturer’s instructions. cDNA samples (5 ng) 
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were amplified in triplicate with the TaqMan 710 Gene Expression Assay (Applied 
Biosystems) and an ABI/Prism 7900 HT thermocycler (Applied Biosystems). Preparations 
of RNA template without reverse transcriptase were used as negative controls.  	  
2. 18 Sphere assay 
After two washes in PBS (Lonza) to carefully eliminate serum, ID8 cells were detached 
from tissue-culture plate using Trypsin EDTA (BE17-161E, Lonza). Cells were counted 
and cultured under non-adherent condition on Poly(2-hydroxyethylmethacrylate)-treated 
(P3932-25G, Sigma) 6 well plates. Cells were cultured in serum-free medium 
(DMEM/F12, 1% PEN-STREP (Lonza), 1% L-Glutamine (Lonza), B27 supplement 
(Gibco), EGF 20 ng/mL, FGF 10 ng/mL) mixed with luEC-L1-derived CM or luEC-mock-
derived CM in 3:1 ratio. Cells cultured in serum-free medium without CM (no CM) were 
used as control. For each condition 500 cells/well were plated in a final volume of 2 mL, in 
triplicate. After 5 days in culture, spheres were counted and the sphere forming efficiency 
(SFE) was calculated as the percentage of the ratio between the total number of spheres 
and the total number of cells seeded. 
 
2. 19 FGFR1 silencing in luECs by shRNA 
Lentiviruses were generated by transient transfection of HEK293T cells with 10 µg of four 
shRNA for mouse FGFR1 (GeneCopoeia, No BC033447.1) or of the scrambled control, 
together with the packaging vectors pMD2.G (Addgene, plasmid #12259), pRSV-Rev 
(Addgene, plasmid #12253), pMDLg/pRRE (Addgene, plasmid #12251), by calcium 
phosphate precipitation. After 24 hours of incubation at 37°C, the cell supernatants were 
collected 24 hours and 48 hours after transfection and filtered with a 0.45-µm filter. The 
lentiviral particles were added to luEC-L1 or luEC-mock (3×105 cells/well) cultured in 
gelatin-coated 6-well plates. 24 hours after infection, 2ug/mL puromycin was added to 
luECs in culture to select only endothelial cells efficiently transduced by shRNAs.  
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2. 20 Statistical analysis 
Student’s two-tailed t-test was used to determine the statistical significance. For in vivo 
experiments with intraperitoneal injection of ID8 cells, a Proportion Test or Poisson Rate 
was used to determine the statistical significance. Differences were considered significant 
at p≤0.05. 
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BACKGROUND and RATIONALE  	  
In a paper recently published from our lab 41, we described for the first time the pivotal, 
cell-autonomous role of endothelial L1 in pathological vasculature. In particular, the 
function of L1 in tumor angiogenesis was studied in a conditional knockout mouse model. 
The endothelial-specific ablation of L1 in mice was achieved by crossing transgenic mice 
expressing Cre-recombinase under the control of the endothelial-specific Tie2 promoter 111 
with L1fl mice carrying two floxed alleles of the L1cam gene 112. The resulting Tie2-
Cre;L1fl mice were used to set up an orthotopic, syngeneic model of pancreatic carcinoma, 
based on the injection of the murine pancreatic cancer cell line Panc02 into the head of the 
pancreas. This approach revealed that vascular L1 deficiency results in decreased tumor 
growth and tumor angiogenesis. Consistent with the notion that cancer-associated 
vasculature is irregular and disorganized (See Introduction), tumors from control mice 
showed impaired vascular maturation and the loss of endothelial polarity. Notably, this 
alterations were reverted by the mere ablation of endothelial L1, which was sufficient to 
promote vascular normalization, as shown by restored pericyte coverage and endothelial 
polarity 41, thus implicating L1 in the aberrant phenotype of cancer vessels.  
These results implied that L1 could be a therapeutic target for preventing tumor neo-
vascularization and the consequent dissemination of cancer cells. Indeed, the treatment of 
tumor-bearing mice with a polyclonal antibody against the extracellular domain of L1 led 
to a significant reduction of tumor growth, accompanied by decreased tumor 
vascularization and by vascular normalization 41. 
The role of L1 in tumor vasculature was also studied in vitro, manipulating L1 expression 
in murine lung-derived endothelial cells (luECs), which express low levels of endogenous 
L1. In this model system, forced L1 over-expression induced cell proliferation, migration 
and tubulogenesis. Moreover, the gene expression profile of L1-overexpressing versus 
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control cells revealed a general up-regulation of genes associated with neo-vascularization 
and with endothelial-to-mesenchymal transition. 
All these findings have provided the rationale for my PhD project, which has focused on 
the role of endothelial L1 as a master regulator of cancer vessel function. Since ovarian 
carcinoma (OC) is a tumor that is strictly dependent on angiogenesis and has shown 
promising results in studies with anti-angiogenic treatments, I have focused my project in 
studying the functional role of vascular L1 in OC and the crosstalk between the 
microenvironment and OC. Such a choice was also supported by the long-standing interest 
and expertise of our lab in this tumor type. 
My PhD project aims at defining the role of vascular L1 in ovarian tumorigenesis and at 
dissecting L1’s function in endothelial cells at the cellular and molecular level. Thus, my 
findings will contribute to a deeper understanding of the biological mechanisms that drive 
OC progression, and they may also pave the way for novel anti-angiogenic strategies that 
would improve the clinical management and the prognosis of OC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
	   51	  
3 RESULTS 	  
3. 1 Endothelial L1 deficiency reduced tumor dissemination in mice 
Recent work published by our group has capitalized on a mouse model of pancreatic 
cancer to show that endothelial L1 is causally involved in the aberrant morphology and 
function of tumor-associated vasculature 41. Based on the key role that the vascular system 
plays in ovarian cancer (OC) development and progression 113 a crucial objective of our 
work is to test whether vascular L1 has a functional role in OC malignancy. To assess the 
clinical relevance of our approach, we first checked the expression of vascular L1 in a 
cohort of human OC samples. A preliminary screening on a series of samples has revealed 
that L1 is expressed at high level in OC vessels (Figure. 12 A and 12 C), while no or little 
expression was found in normal ovaries (Figure. 12 B and 12 C).  
 
 
 
Figure 12. Vascular L1 expression in OC and normal ovary.  
Tissue section from human ovarian carcinoma (A) and from normal ovary (B) stained for 
L1. The tumor vasculature exhibits markedly higher levels of L1 (arrows) in comparison to 
its normal counterpart where few vessels are L1-positive. (C) Quantification of L1-
expressing vessels in ovarian carcinoma and normal ovary (n=10) (*** p ≤ 0 .005). 
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To define the functional role of vascular L1 in OC growth and progression, the expression 
of L1 has been ablated in endothelial cells by crossing Tie2-Cre mice, which express Cre 
recombinase under the control of the Tie2 promoter 111, with mice carrying LoxP-flanked 
alleles of the L1cam gene (L1fl/fl). The Tie2-Cre;L1fl/fl mouse model, extensively 
characterized in our lab 41,100 was combined with a syngeneic model of OC based on the 
murine cell line ID8, previously shown to recapitulate OC development upon orthotopic 
injection into recipient C57BL/6 mice 110. 
Of note, ID8 cells did not express L1 endogenously, either at mRNA level (Figure. 13) or 
at protein level (Figure. 14). B16-F10 melanoma cell line was used as positive control for 
L1 expression 41. This enabled us to focus, at least for this initial study, specifically on the 
role of host-derived L1 in OC growth and dissemination, ruling out the contribution (yet 
possible and even likely in other model systems) of tumor-derived L1. 
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Figure 13. ID8 ovarian cancer cell line did not express L1 endogenously at mRNA level. 
Total RNA was extracted from ID8 cells and the expression level of L1 was measured by 
qRT-PCR. Results were normalized on the expression of the housekeeping genes GAPDH 
and 18S. Since the expression of L1 in ID8 cells was nearly undetectable (Ct=37), we used 
B16-F10 melanoma cells as positive control 41 (n.d., not detectable). 
 
 
Figure 14. ID8 mouse ovarian cancer cell line did not express L1 protein. 
Immunoblot analysis of ID8 cells revealed that they did not express L1 protein 
endogenously. B16-F10 mouse melanoma cell line was used as positive control for L1 
expression 41. b-actin served as loading control. 
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The intra-peritoneal injection of ovarian cancer cells is widely used as an orthotopic model 
that mimic the advanced stage of the human disease, characterized by the dissemination of 
OC cells in the peritoneal cavity. Thus, we transplanted Tie2-Cre;L1fl/fl and L1fl/fl (control 
group) mice with 106 ID8 cells by intra-peritoneal injection. To facilitate the detection and 
quantitation of tumor implants in the abdominal cavity of mice, we took advantage of ID8 
cells stably expressing GFP (ID8-GFP). In agreement with previous work 114, one month 
after the injection tumor implants were detected in several peritoneal sites, such as 
mesentery and abdominal wall (Figure. 15). 
We first confirmed the ablation of L1 in the OC vasculature of Tie2-Cre;L1fl/fl by 
comparing Tie2-Cre;L1fl/fl ID8 tumor-bearing with control mice (Figure. 16). Importantly, 
nerves of Tie2-Cre;L1fl/fl mice retained the expression of L1 (Figure. 16), thus serving as 
an internal control and confirming the specificity of the genetic inactivation of L1 in the 
tumor vasculature. This phenotype was accompanied by a reduction of ID8 tumorigenicity: 
while 100% of control L1fl/fl mice developed tumors in the omentum and 87.5% in the 
abdominal wall, these were present only in 62.5% and 50%, respectively, of Tie2-Cre;L1fl/fl 
(Table 1). Moreover, counting GFP-expressing ID8-implants per mouse revealed a 
statistically significant decrease in the number of lesions in the omentum, abdominal wall 
and diaphragm of Tie2-Cre;L1fl/fl mice (Figure. 17). 
All these data supported the hypothesis that vascular L1 contributes to OC malignancy and 
provided the rationale for exploring the underlying mechanisms. 
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Figure 15. ID8-GFP based OC model. 
ID8-GFP cells were injected intra-peritoneally in L1fl/fl and Tie2Cre;L1fl/fl mice. 
Representative images of GFP-expressing ID8 tumor implants in mesentery and 
abdominal wall of L1fl/fl (left panel) and Tie2Cre;L1fl/fl (right panel) mice at the time of 
sacrifice. ID8 model closely resemble the human disease.  
 
 
 
Figure 16. Ablation of L1 in tumor-associated vasculature of Tie2Cre;L1fl/fl mice 
Immunofluorescence analysis of frozen section derived from ID8 tumor implant grown on 
the abdominal wall of Tie2Cre;L1fl/fl (right panel) and control mice (left panel). Co-
staining for L1 (red) and the endothelial marker CD31 (white) showed L1-expression in 
tumor vessel of L1fl/fl mice while no expression was found in the vasculature of 
Tie2Cre;L1fl/fl tumor. The green arrow indicates L1-expressing nerves. 
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Table 1. Vascular L1 deficiency affects tumor burden. 
L1fl/fl (n=8) and Tie2Cre; L1fl/fl (n=8) mice were transplanted intraperitoneally with 106 
ID8-GFP cells. Vascular L1 deficiency reduces the number of mice with tumor implants in 
the omentum and in the abdominal wall.  	  
  
 
Figure 17. Vascular L1 deficiency affected OC peritoneal dissemination.  
L1fl/fl (n=8) and Tie2Cre;L1fl/fl (n=8) mice were transplanted intra-peritoneally with 106 
GFP-expressing ID8 cells. After 30 days, GFP-positive neoplastic lesions in different 
peritoneal organs were counted. Vascular L1 deficiency reduced the number of tumor 
implants in the omentum, abdominal wall and diaphragm (*p≤0.05; ***p≤0.005). 
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3. 2 The crosstalk with FGFR signaling underlies multiple functions of L1 in 
tumor vasculature.  
L1 is known to regulate several cellular processes by interacting with and activating 
signaling receptors. In particular, data previously generated in our lab showed that L1-
induced cancer cell migration and invasion are mediated by fibroblast growth factor 
receptor (FGFR) 104. Given the pivotal role of FGFR signaling in tumor angiogenesis 115, 
we hypothesized that L1-induced EC activation might be mediated at least in part by 
FGFR. We tested this hypothesis in mouse immortalized lung ECs (luECs; 41). In 
agreement with previous reports on endothelial cells 116, luEC express only FGFR1, while 
no detectable expression of FGFR2, FGFR3 and FGFR4 was observed (data not shown).  
To test whether FGFR signaling was involved in L1-induced EC processes 41, we 
performed a series of in vitro experiments preventing FGFR activation with the chemical 
inhibitor PD173074, that was demonstrated to be highly selective for FGFR 117. The 
treatment of L1-overexpressing ECs (luEC-L1) with PD173074 reduced significantly L1-
dependent endothelial cell proliferation (Figure. 18), migration (Figure. 19) and tube 
formation (Figure. 20) as compared to control ECs (luEC-mock). This implicated FGFR as 
a crucial effector in the L1-dependent regulation of key angiogenesis-related events. Our 
previous data pointed to L1 as a novel regulator of the transcriptional activity in ECs 41. 
This raised the possibility that FGFR is involved at least partially in L1-regulated 
endothelial gene expression. To test this hypothesis, we performed an Affymetrix 
screening of luEC-L1 and luEC-mock cultured in the presence of PD173074. This 
analysis, indeed, highlighted a set of genes that were modulated by L1 in vehicle-treated 
but not in PD173074-treated cells (Figure. 21), pointing to an L1-dependent, FGFR-
mediated regulation of gene expression. 
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Figure	  18. L1-induced EC proliferation required FGFR signaling.  
L1-overexpressing ECs and control cells were cultured in presence of the FGFR inhibitor 
(PD173074) or vehicle only (DMSO). Curves show the quantitation of EC proliferation at 
0, 24, 48 and 72 hours after culturing (*** p <0.005). 
 
	  
Figure 19. L1-induced EC migration required FGFR signaling.  
Covered distance of migration of mock and L1 transfected luECs in presence of the FGFR 
inhibitor PD173074 or vehicle only (DMSO) (** p <0.05; ns =not significant).  
	   59	  
	  
Figure 20. L1-induced EC tube-formation required FGFR signaling.  
Quantitation of tube-formation on mock and L1 transfected luECs in presence of the FGFR 
inhibitor PD173074 or vehicle only (DMSO) (*** p <0.005).  
 
 
 
Figure 21. L1 regulated a set of genes in FGFR1-dependent manner.  
Heatmap of genes regulated by L1 in luECs which are no longer regulated in the presence 
of the FGFR inhibitor PD173074. Red, upregulated; green, downregulated. 
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To validate these data with an alternative and FGFR1-specific approach, we genetically 
inactivated mouse FGFR1 employing four different shRNAs (sh1, sh2, sh3 and sh4). qRT-
PCR analysis confirmed that FGFR1 expression was reduced both in luEC-L1 and luEC-
mock by about 70% with sh1 and by about 40% with sh2 and sh4, as compared with a 
scramble shRNA. Sh3, instead, decreased FGFR1 expression of about 20% in luEC-mock 
and about 50% in luEC-L1 (Figure. 22).  
 
 
Figure 22 . Genetic inactivation of mouse FGFR1 in luECs.  
Mouse FGFR1 was silenced by four different shRNA in luEC-L1 and luEC-mock. After five 
days of puromycin selection, RNA was extracted from antibiotic-resistant luECs and qRT-
PCR was performed to measure the expression of FGFR1. The downregulation of FGFR1 
expression by shRNA was statistically significant (p ≤ 0,05) for all the shRNA as compared 
to the scramble shRNA (negative control). 
 
 
Since the sh1 (hereafter referred as sh-FGFR1) showed the highest efficiency in decreasing 
FGFR1 expression in both luEC-L1 and luEC-mock, we selected this shRNA for further 
experiments. In order to validate the results obtained with PD173074 chemical inhibitor, 
FGFR1-silenced luECs were subjected to tube formation assays in matrigel. The down-
	   61	  
modulation of FGFR1 by shRNA impaired L1-dependent capability of endothelial cells to 
form tube structures (Figure. 23), thus confirming the results obtained with the chemical 
inhibitor. 
 
 
Figure 23. L1-induced EC tube formation requires FGFR signaling.  
After FGFR1 silencing by shRNA, luECs were plated on matrigel-coated wells to form 
tube like structures. Bars represent the number of tube-like structures formed by mock and 
L1 transfected luECs after the genetic inactivation of FGFR1 by shRNA. Scramle shRNA 
was used as negative control (*** p ≤ 0,005). 
 	  
We also attempted to validate the PD173074 data on L1-regulated gene expression with 
shRNA-mediated ablation of FGFR1. To this goal, we performed a quantitative traits 
analysis of the data obtained from the above mentioned Affimetrix analysis (Figure. 21). 
Briefly, this tool allows finding genes that correlate significantly with a specified 
quantitative variable (called trait). In our case it is the L1-induced and FGFR-dependent 
regulation of genes in endothelium. In our experiment, each gene derived from Affimetrix 
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analysis that follows the trait was scored with a correlation coefficient and with a p-value. 
A coefficient higher than 0.7 means that the gene analyzed has a strong correlation with 
the trait studied. Based on this analysis, we selected the following four genes regulated by 
L1 in FGFR1-dependent manner: Egr1, Robo4, Rab5b and Sipa1 (Table 2). These 
candidates were selected because they were significantly regulated by L1 in a FGFR-
dependent manner and because of biological considerations. Indeed, both Robo4 118,119 and 
Egr1 120,121 have been already described as pivotal players in tumor angiogenesis and/or in 
vessel architecture. Conversely, the involvement of Rab5b and Sipa1 proteins in tumor 
angiogenesis has been poorly described and their novelty in this field make them 
particularly appealing for further studying. Our qRT-PCR data confirmed the L1-mediated 
up-regulation of all the selected candidates (Figure. 24, blue bars). Moreover, upon FGFR1 
inactivation by shRNA, the expression of all these genes was significantly reduced (Figure. 
24, red bars) confirming that their expression was mediated by FGFR1 in endothelial cells. 
Overall, our data highlighted a novel interplay between L1 and FGFR that orchestrates 
important biological processes in endothelial cells.  
 
 
Table 2. Genes up-regulated by L1 in FGFR1-dependent manner.  
List of genes selected from Affimetrix analysis performed on luEC-L1 and luEC-mock in 
the presence of PD173074 or vehicle (DMSO). These genes were up-regulated by L1 and 
their regulation no longer occurred upon treatment with the FGFR inhibitor PD173074.  
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Figure 24. qRT-PCR analysis of Egr1, Rab5b, Robo4 and Sipa1 genes in luEC-L1 and 
luEC-mock after FGFR1 inactivation by shRNA.  
Total RNA was extracted from luEC-L1 and luEC-mock after FGFR1 inactivation by 
shRNA. The expression of Egr1, Rab5b, Robo4 and Sipa1 genes was evaluated by qRT-
PCR. The expression of all genes was induced by L1: blue bars represented the expression 
of each gene in luEC-L1 as compared to luEC-mock. Upon FGFR1 inactivation, the L1-
induced up-regulation all genes was reverted. Red bars represented the expression of these 
genes in luEC-L1 silenced with sh-FGFR1 normalized to the expression of the same gene 
in luEC-L1 transduced with scramble shRNA. 
 
 
3. 3 Vascular L1 regulated the crosstalk between microenvironment and tumor 
cells: implications for ovarian cancer growth and for cancer stem cell function. 
Tumor epithelial cells coexist in carcinomas with several distinct stromal cell types that 
together create the tumor microenvironment. In the last years, many groups have 
highlighted the contribution of the microenvironment to the development of a variety of 
tumors. The accumulated evidence indicates that tumor cells actively recruit stromal cells, 
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such as inflammatory cells, vascular cells, and fibroblasts 8,122 , into the tumor, and that this 
recruitment is essential for the generation of a microenvironment that actively fosters 
tumor growth 123. In particular, many groups have reported the existence of a signaling 
crosstalk between tumor cells and ECs that enhance tumor growth in cell contact-
dependent 124 as well as independent manner 125. 
Based on these considerations as well as on our previous data that showed reduced tumor 
growth upon endothelial ablation of L1 41, we asked whether vascular L1 modulates 
ovarian cancer growth. To this end, GFP-expressing ID8 cells were co-injected 
subcutaneously into immunodeficient NOD/SCID/IL2Rgnull mice with either luEC-L1 or 
luEC-mock. We tested two different ID8:luEC ratios, 1:1 and 5:1. As soon as 8 (1:1 ratio) 
or 15 days (5:1 ratio), all transplanted mice showed the formation of hemangioma-like 
structures (Figure. 25 and 26), reflecting the fact that ECs overgrew ID8 cells. This result 
was most likely due to the combination of two factors: the immortalization of luECs with 
polyoma middle-T-antigen which indeed might underlie hemangiomas in vivo 41,109 and the 
relatively slow growth rate of ID8 cells when transplanted subcutaneously 126,127. 
Nevertheless, we undertook this co-transplantation approach to assess whether L1-
overexpressing endothelial cells exerted a sort of “priming” effect on ID8 cells. To this 
goal, first-generation tumors (consisting of small ID8 masses plus luEC-derived 
hemangiomas) were enzymatically digested and GFP-expressing ID8 cells were purified 
from cell suspension by FACS-sorting. Then, ID8 cells were re-transplanted alone into 
NOD/SCID/IL2Rgnull mice to form second-generation tumors. Notably, ID8 cells derived 
from the co-transplantation with luEC-L1 were more tumorigenic as compared with 
control cells (Figure. 27), suggesting that L1-expressing EC had somehow “primed” OC 
cells enhancing their tumorigenic activity.  
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Figure 25. Co-transplantation of ECs and ID8 cells resulted in the formation of 
hemangioma-like structures.  
GFP-expressing ID8 cells were injected subcutaneously into NOD/SCID/IL2Rgnull mice 
admixed with luEC-L1 or luEC-mock (1:1 ratio); bars indicate the volume of 
hemangiomas (n=5) at the endpoint of the experiment.  
 
 
 
Figure 26. ID8 cells mixed with luECs developed hemangioma-like structure in 
immunocompromised mice.  
H&E staining of tissue section from hemangiomas lesions derived from ID8 cells 
transplanted subcutaneously together with luEC-L1 (A) or luEC-mock (B) in 
NOD/SCID/IL2Rgnull mice (n=5). These representative images highlighted two typical 
characteristics of haemangioma: the presense of newly formed vessels (green arrows) and 
the accumulation of red blood cells (black arrows). 
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Figure 27. Serial transplantation of ID8 cells primed by L1-overexpresing luECs showed 
enhanced tumorigenicity. 
GFP-expressing ID8 cells mixed with luECs were transplanted subcutaneously in 
NOD/SCID/IL2Rgnull mice. After enzymatic digestion of tumors, GFP expressing ID8 cells 
were purified by FACS-sorting and retransplanted into mice at 2x104 cells/mouse (n=2). 
Curves show the kinetic of tumor growth of ID8 cells primed with luEC-L1 (blue) or luEC-
mock (red). 
 
To determine if the direct cell-cell contact was required for such a pro-tumorigenic effect 
of L1-overexpressing luECs, we performed a similar experiment but this time using 
conditioned medium (CM) collected from luEC-L1 or from luEC-mock. In particular, 
NOD/SCID/IL-2 Rgnull mice were transplanted with ID8 cells admixed with either luEC-
L1- or luEC-mock-derived CM (our control). Interestingly, luEC-L1-derived CM was 
sufficient to enhance OC growth while luEC-mock-derived CM had no effect (Figure. 28), 
suggesting that vascular L1 is able to modulate tumor growth also in cell-contact 
independent manner.  
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Figure 28. LuEC-L1-derived CM promoted OC growth in vivo.  
GFP-expressing ID8 cells were injected subcutaneously into NOD/SCID/IL2Rgnull mice 
(n=10), alone or admixed with CM from luEC-L1 or from luEC-mock, and tumor growth 
was monitored. ID8 cells co-transplanted with luEC-L1-derived CM formed tumors with a 
higher growth rate than cells co-transplanted with luEC-mock-derived CM (** p<0.05). 
 
The capability of either luEC-L1 cells or luEC-L1-derived CM to foster tumor formation 
might be associated with the acquisition by tumor cells of markers associated with 
epithelial-mesenchymal transition (EMT). The latter, indeed, is a hallmark of cancer 
progression, and the expression of EMT related markers correlates with a more aggressive 
behavior of tumor cells and eventually with an increased metastatic potential 128,129. Of 
note, we have already demonstrated that L1 induces the expression of EMT-related genes 
41. For all these reasons, we analyzed EMT markers in tumors derived from ID8 cells 
mixed with luEC-L1- or luEC-mock-derived CM. A preliminary analysis of a panel of 
EMT-related genes on tumor samples revealed that luEC-L1-derived CM induced the 
expression of the EMT-related genes Cdh2, Vim, Zeb1, Zeb2, Snail1, Twist and Klf4 while 
it caused the down-regulation of the epithelial marker Krt8 (Figure. 29), indicating that L1-
dependent induction of EMT occurs in vivo. 
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Figure 29. LuEC-L1-derived CM induced the expression of EMT-related genes in vivo.  
Total RNA was extracted from paraffin-embedded tumors derived from ID8 cells admixed 
either with luEC-L1- or luEC-mock-derived CM (n=2). EMT-related genes were analyzed 
by qRT-PCR. Bars represent the level of expression of EMT-related genes. luEC-L1-
derived CM induced the expression of a series of EMT-genes and it determined the down-
regulation of the epithelial marker Krt8.  
 
Besides supporting tumor cell invasion, EMT correlates with the acquisition of cancer-
initiating properties by tumor cells. Indeed, the expression of EMT genes is frequently 
accompanied by the expression of genes related to tumor-initiating cells or CSCs 42,130. In 
agreement with this notion, we noticed that ID8 cells primed with luEC-L1 formed tumors 
that were already palpable after 19 days post-injection, while tumors from ID8 cells 
primed with luEC-mock became palpable after 26 days (Figure. 30). The latency of ID8 
cells exposed to luEC-L1-derived CM was also significantly shorter than that of cells co-
transplanted with luEC-mock-derived CM (Table. 3), implying that the direct contact of 
L1-expressing ECs with tumor cells is dispensable for the effect on tumor initiation. 
Overall these data showed that vascular L1 decreases OC tumor latency and promotes 
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tumorigenesis, concomitant to the induction of EMT. Our finding highlighted the pivotal 
role of L1 in microenvironment-regulated OC growth. 
 
 
 
Figure 30. ID8 cells primed with L1-overexpressing luEC cells showed a decreased 
latency in mice. 
GFP-expressing ID8 cells mixed with luECs were transplanted subcutaneously in 
NOD/SCID/IL2Rgnull mice. After enzymatic digestion of tumors, GFP expressing ID8 cells 
were purified by FACS-sorting and retransplanted into mice at 2x104 cells/mouse (n=2). 
Bars show a reduction in the latency of ID8 tumors. While ID8 cells primed with luEC-L1 
formed tumors by 19 days after transplantation (blu bar), ID8 cells primed with luEC-
mock became visible 7 days after (red bar). 
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Table 3. LuEC-L1 derived CM decreased ID8 tumor latency in mice. 
GFP-expressing ID8 cells were mixed with CM derived from luEC-L1 or luEC-mock and 
were transplanted subcutaneously in NOD/SCID/IL2Rgnull mice (n=10). While ID8 cells 
mixed with luEC-L1 derived CM formed tumors by 61 days after transplantation, ID8 cells 
mixed with luEC-mock derived CM became visible 69 days after the beginning of the 
experiment.  
 
 
3. 4 Vascular L1 induced stemness in OC cells 
An increasing body of evidence supports the notion that tumor initiation is accounted for 
by the sub-population of the so-called tumor-initiating cells or CSCs. These cells often 
reside in specialized microenvironment, which are localized in the close proximity of 
tumor vessel, called perivascular niches, where a cross-talk with endothelial cells is crucial 
for their survival 47. Since our in vivo experiment showed that luEC-L1-derived CM 
promoted tumor initiation, to verify whether vascular L1 promotes ovarian CSC (OCSC) 
function, we performed a sphere formation assays. This is a widely used technique for 
determining CSC frequency in a cell population and it is an indirect measure of inherent 
stemness-associated biological properties 131. In particular, we cultured a low number of 
ID8 cells under non-adherent conditions to form monoclonal spheroids, in the presence of 
either luEC-L1- or luEC-mock-derived CM. The addition to the culture of luEC-L1-
derived CM enhanced the percentage of ID8 cells able to form spheres (Figure. 31) as 
compared with luEC-mock-derived CM or ID8 cells cultured in absence of CM (“no 
CM”), supporting a role of vascular L1 in promoting the OCSC phenotype.  
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Figure 31. LuEC-L1-derived CM increased the capability of ID8 cells to growth as 
spheres.  
ID8 cells were cultured under non-adherent conditions at very low concentration (500 
cells/ml) in the presence of CM from luEC-L1 or luEC-mock (or no CM). After 5 days, 
clonal spheres were counted and the sphere-forming efficiency (SFE) was determined as 
the percentage of cells from the original cultures able to form spheres. The addition of 1/3 
of luEC-L1-derived CM to the culture increased the SFE of ID8 cells as compared to CM 
from luEC-mock or to medium without CM (*** p<0.005). 
 
 
Our data showed that CM derived from L1-overexpressing luECs is able to promote CSC-
related properties to OC cells in vitro and in vivo, as shown by sphere formation and tumor 
initiation data. In an attempt to identify the molecule(s) able to confer this phenotype to 
OC cells, we took advantage of results recently published from our lab where we showed 
that luEC-L1 secrete IL-6 in conditioned medium derived from endothelial cells 41. IL-6 
has a critical role in promoting a cancer stem cell-phenotype in several neoplasms such as 
breast and brain tumors 132,133, thus implying that this molecule may act downstream of 
vascular L1 to promote ovarian tumor initiation and cancer growth. To test whether 
vascular IL-6 mediates the L1-induced acquisition of OCSC traits, ID8 cells were 
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subjected to sphere formation assays in the presence of luEC-L1-derived CM previously 
depleted of IL-6 by immunoprecipitation. IL-6 depletion abolished the sphere-forming 
capability induced by luEC-L1-derived CM, demonstrating that this secreted molecule has 
a critical role as an L1 effector in promoting CSC phenotype (Figure. 32).  
 
 
 
Figure 32. IL-6 mediates L1-induced sphere forming ability in ID8.  
ID8 cells were cultured under non-adherent conditions at very low concentration (500 
cells/ml) in the presence of CM from luEC-L1 or luEC-mock (or no CM) depleted from IL-
6 by immunoprecipitation. After 5 days, clonal spheres were counted and the sphere-
forming efficiency (SFE) was determined as the percentage of cells from the original 
cultures able to form spheres. The depletion of vascular IL-6 from luEC-L1-derived CM 
reduced nearly by 50% the SFE of ID8 cells as compared to luEC-L1 derived CM (*** 
p<0.005). 
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4 DISCUSSION 
The expression of L1 in tumor-associated vasculature has been reported for several tumor 
types, including breast, ovarian and pancreatic carcinoma 100,108. Our group has also 
demonstrated that L1 plays a functional role in tumor vasculature. Indeed, endothelial L1 
deficiency results in reduced tumor growth and tumor angiogenesis, while it promotes 
vascular normalization. Moreover, the treatment of tumor-bearing mice with a polyclonal 
anti-L1 antibody mimics the genetic inactivation of L1 41, thus pointing to L1 not only as a 
marker of pathological angiogenesis but also as a novel potential target for anti-angiogenic 
therapy.  
Based on these findings, one of the main objectives of my project was to test whether 
vascular L1 is involved also in OC malignancy. In this context, a deeper understanding of 
the molecular mechanisms that drive vessel pathophysiology in OC is likely to have 
important implications, given that the vascular system plays a pivotal role in OC and the 
addition of VEGF-based anti-angiogenic drugs to standard chemotherapy gave promising 
results in clinics 77.  
Using a syngeneic orthothopic model of OC based on the ID8 ovarian cancer cell line we 
have demonstrated that vascular L1 deficiency reduced the tumorigenicity and the 
dissemination of ID8 ovarian cancer cells in the abdominal wall, in the omentum and in the 
diaphragm of mice, typical sites of OC spreading also in patients. These results suggest 
that the expression of L1 in tumor vasculature offers a growth advantage for ID8-derived 
tumor implants. Indeed, it is plausible that OC cells adhere to several organs in the 
abdominal cavity of mice but that their growth up to measurable tumor lesions requires L1-
mediated angiogenesis.  
The clinical relevance and the possible translational application of our in vivo results were 
supported by the immunohistochemical analysis of vascular L1 expression in human OC 
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versus its normal counterpart. Interestingly, L1 is expressed in 80% of vessels in OC 
samples while only 20% of vessels expressed L1 in normal ovaries.  
The results obtained in OC mouse model together with the immunohistochemical analysis 
performed on human samples pointed to L1 as a potential target in the context of 
pathological angiogenesis. Notably, even if the VEGF- based anti-angiogenic therapy gave 
promising results in OC patients, the appearance of cancers able to resist/escape to therapy 
represents one of the main limits to the use of such drugs in clinics 35. Therefore, the 
identification of new vascular mechanisms and targets is an urgent need, and L1 might 
represent a suitable candidate to develop innovative anti-angiogenic drug and overcome 
the current limitations of anti-angiogenic therapy. Moreover, its expression at the cell 
surface together with its abundance in tumor vasculature (as compared with the normal 
counterpart), make L1 particularly appealing for further studying and drug development. 
Another important aspect of L1 function in endothelium is its involvement in vessel 
architecture 41. L1-expressing vasculature showed abnormal polarity, loss of VE-cadherin-
mediated endothelial junction and increased permeability. As a consequence, vascular L1 
deficiency resulted in decreased vessel permeability and vascular normalization 41. 
Although the concept of “vascular normalization” and its therapeutic significance are very 
debated in the field 11, both preclinical 29 and clinical studies 32,34 have provided evidences 
of improved vascular maturation and stability upon treatment with anti-angiogenic drugs.  
Furthermore, the existence of a “normalization window”, as a consequence of anti-
angiogenic treatment, might help in solving the apparent paradox represented by the fact 
that anti-angiogenic agents boost the efficacy of chemotherapy 134. Indeed, several studies 
have showed an increase in chemotherapeutics uptake within the tumor after anti-
angiogenic treatment 135,136. In other cases, although the concentration of 
chemotherapeutics in the tumor mass decreased upon anti-angiogenic treatment 137,138, it is 
associated with a slower efflux of these agents from the tumor, thus prolonging the time of 
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contact between tumor cells and drugs. Moreover, independently from the amount of drug 
able to reach the tumor, a normalized vasculature results in a more homogeneous 
intratumoral distribution of anticancer therapies 137. These findings in preclinical model 
might help explaining also the results obtained in recent clinical trials in OC patients, in 
which the addition of Bevacizumab to standard chemotherapy increased the PFS as 
compared to treatment with chemotherapy only.  
In this context, the simultaneous administration of an L1 inhibitor as anti-angiogenic and 
vascular-normalizing agent together with standard chemotherapy might result in a 
synergistic effect with significant clinical benefit for OC patients. Of course, the toxicity 
related to inhibiting L1 remains an issue that needs to be addressed, however, earlier 
reports on preclinical models 41,105,107 support the feasibility. For example, the treatment of 
tumor-bearing mice with a polyclonal anti-L1 antibody showed no significant side effects 
41 while it determined a reduction in tumor angiogenesis, tumor growth and metastasis 41, 
supporting the potential translational application of these findings. 
 
These in vivo findings were supported by several experiments performed in vitro, using 
luECs. The main objective of this part of this work was to further characterize the 
molecular mechanisms underling the multiple function of L1 in endothelium 41. We have 
previously demonstrated that the up-regulation of L1 in ECs induced cell migration, 
proliferation and tube formation 41. Moreover, the ectopic expression of L1 in ECs 
determined the regulation of genes involved in angiogenesis, EMT and cell proliferation 41. 
However how this cell adhesion molecule modulates all these process in endothelium 
remain elusive. 
Based on the notion that L1-induced cancer cell migration and invasion are mediated by 
fibroblast growth factor receptor (FGFR) 104 and that the FGF/FGFR signaling pathway 
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plays a pivotal role in angiogenesis 115, we investigated a possible relationship between L1 
and FGFR in endothelium. These experiments revealed the involvement of FGFR in L1-
dependent regulation of endothelial cell proliferation, migration and tube formation. 
Although we have not investigated the molecular basis of such interplay between FGFR 
and L1, a possible mechanism might be represented by a direct interaction between 
vascular L1 and FGFR. This hypothesis is supported by the fact that L1 engages in 
heterophilic interactions with RTKs and that a direct binding of L1 to FGFR1 has been 
already demonstrated 139,140. In endothelial cells, surface-bound L1 could stimulate FGFR 
activation by cis interaction as well as by trans interactions upon cell-cell contact. 
Alternatively, it has been established that L1 can undergo proteolytic cleavage that results 
in the shedding of its biologically active ectodomain 94,96,141. The latter could act as a 
soluble ligand for FGFR, thus promoting endothelial cell proliferation, migration and tube 
formation. Another key aspect that future studies should address is whether L1 exerts a 
direct and autonomous role on FGFR activation or it rather modulates the response of the 
receptor to its classical ligand, FGF. In this context, our group has previously demonstrated 
that the L1-related molecule NCAM not only acts as a direct activating ligand for FGFR 
eliciting a response that is divergent from that elicited by FGF 142, but it also negatively 
regulates the binding and the biological activity of FGF itself 143. On the other hand it is 
also conceivable that L1 acts in a synergistic manner with FGF, for example by preventing 
the rapid internalization and degradation of FGFR upon ligand binding, thus resulting in 
sustained signaling and endothelial cell activation. 
The broad spectrum of FGFR-mediated biological processes induced by L1 in endothelial 
cells is consistent with the large series of genes that are modulated by L1 via FGFR, which 
implies a massive influence of this crosstalk on gene transcription. Based on these 
considerations and on the well established pro-angiogenic role of FGF/FGFR signaling 
pathway in tumor angiogenesis and the aberrant phenotype correlated with L1-expression 
in tumor vasculature, a deeper understanding of their molecular interplay and/or their 
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integrated regulation of other signaling pathways, might be an important step for the 
design of novel anti-angiogenic therapy. Indeed, it is already known that FGFR signaling 
cascade is activated to compensate the VEGF-deprivation upon VEGF-based anti-
angiogenic therapy 35. Moreover, anti-FGF/FGFR compounds are already used in clinics, 
even if with non-negligible side effects 144. The simultaneous block of L1 and FGFR might 
represent a novel and more effective anti-angiogenic therapy to treat OC patients. 
Moreover, the use of a putative anti-L1 drug might result in the indirect blocking of several 
genes/pathways expressed and/or regulated by FGFR activation and it might represent a 
strategy to overcome the toxicity of FGFR inhibitors.  
 
Another intriguing function of ECs in tumors is represented by their active role in fostering 
tumor growth. In this view, ECs not only provide tumor with the physical structure to 
allow blood flow but they also express/secrete molecules able to promote cancer growth. 
Indeed, several studies have highlighted the existence of a signaling crosstalk between 
tumor cells and ECs that actively promotes tumor growth 124. Notably, our data indicate 
that vascular L1 promotes OC growth in vivo. Indeed, the serial transplantation of ID8 OC 
cells “primed” with luEC-L1 showed an enhanced tumorigenicity as compared with the 
same cells co-transplanted with control ECs. Moreover, we have demonstrated that the 
cell-cell contact is dispensable for the pro-tumoral effect of L1-overexpressing luECs. 
Indeed, luEC-L1-derived CM is effective in promoting OC growth, suggesting a pro-
tumoral role of factor(s) secreted by L1-overexpressing endothelial cells.  These data 
indicate a role of vascular L1 in fostering OC growth, thus contributing to define a novel 
interplay between microenvironment and tumor cells. 
It has long been known, also based on data from our lab, that L1 is highly expressed in 
cancer cells, including OC cells 104. It is conceivable that tumor-derived L1 acts as a pro-
angiogenic molecule by stimulating EC activation in a paracrine manner. For example, L1 
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expressed in OC cancer cells might induce the activation of FGFR in adjacent vessels. In 
this context, the proteolyitc cleavage of the extracellular domain of L1 92 and the 
consequent release of its soluble form that retains biological activity 96 might reflect the 
ability of tumor cells to generate an L1-derived angiogenic ligand. A further layer of 
complexity to such an intercellular signaling might come from the co-expression of L1 in 
both cancer cells and vascular endothelium. This might promote homophylic L1-L1 
interactions which would likely have a profound impact on the resulting signal. For 
example, since trans L1 binding promotes clustering of the molecule on the cell surface, in 
the case of FGFR these interaction might lead to FGFR clustering and, therefore, to 
amplification of the angiogenic signal. Overall, this hypothesis supports an active role of 
tumor-derived L1 (both surface-bound and/or soluble) in tumor angiogenesis.  
Taken together with our present results, these considerations support the existence of a 
bidirectional crosstalk between ECs and tumor cells in which the two cell types modulate 
each other through L1-mediated signaling. In this scenario, a putative L1-based anti-
angiogenic therapy might have multiple effect, blocking both the cell-autonomous role of 
L1 in tumor vasculature on one hand and in cancer cell on the other, as well as interfering 
with the signaling crosstalk between the two cell types. 
 
The enhanced tumorigenicity of luEC-L1-derived CM seems to be, at least in part, 
associated with the acquisition of EMT-related markers. Although the qRT-PCR analysis 
for EMT-associated genes was performed in a very limited set of samples, it revealed that 
luEC-L1-derived CM promoted the up-regulation of Cdh2, Zeb1, Zeb2, Snail1, Twist and 
Klf4 together with the loss of the epithelial marker Krt8. The role of L1 in EMT has been 
clearly established in various experimental models, especially in cancer cells 102,145. 
However, those studies have documented a cell-autonomous function, whereby the 
expression of L1 per se promoted EMT 146. Our results provide an additional mechanism in 
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which EMT in cancer cells is regulated by vessel-derived L1 in a paracrine manner 
through secreted factors. Future studies should aim at identifying the factors themselves, in 
particular clarifying whether EMT is directly induced by the extracellular domain of L1 
released by ECs in the surrounding environment or rather by molecules that are secreted by 
ECs in a L1-dependent manner. 
 
The EMT process, besides conferring invasive capabilities, is very often intimately linked 
with the acquisition by tumor cells of cancer-initiating properties or cancer stem-like cells 
phenotype 42. The latter hallmarks normally result in shorter tumor latency, which is what 
we observed upon L1 expression in ECs. Indeed, ID8 cells “primed” by the previous co-
transplantation with luEC-L1 or exposed to luEC-L1-derived CM showed a reduction in 
tumor latency as compared with ID8 primed with control cells or exposed to CM derived 
from control cells. While these data support the effect of vascular L1 on tumor initiation, 
the underlying mechanisms remain elusive. Some insights in this regard may come from 
the different results of my two in vivo approaches. Indeed, the re-transplantation of ID8 
cells in mice after priming in vivo with luEC-L1 resulted in tumor formation by 19 days 
after injection, while the pro-tumoral effects mediated by luEC-L1-derived CM became 
visible 60 day after transplantation. This apparent discrepancy in tumor latency might be 
accounted for by the intrinsic difference between the two experimental procedures. Indeed, 
when ID8 cells are co-transplanted with endothelial cells, they are exposed for several days 
to vessel-derived molecules (including L1 itself), both via cell-cell contact and through 
secreted factors. The high impact of this “priming” phenomenon is also demonstrated by 
the fact that the number of ID8 cells required for tumor formation was significantly lower 
in the subsequent transplantation (2x104) as compared to the number in the initial injection 
(1x106), indicating a much higher tumor-initiating ability. In contrast to the long-term 
exposure of ID8 cells to luEC-L1 during the priming period, cells transplanted with luEC-
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L1-derived CM are likely exposed to EC-derived factor for limited time (also due to the 
short half-life of the factors themselves), thus accounting for longer latency. Consistent 
with the decreased tumor latency in vivo, luEC-L1-derived CM increased the capability of 
ID8 cells to form spheres in vitro, further supporting the notion that factors secreted by EC 
under the control of L1 promote OC stemness. 
Overall, these considerations point to L1 as a novel player in the so-called perivascular 
niche, namely the specialized microenvironment where CSCs reside and receive survival 
and proliferation signals from ECs. In the last few years, several groups have focused on 
the characterization of CSC niches and on the possibility to target the EC/CSC interactions 
that occur there 47. Our data suggest that L1 inhibition might contribute to achieve this 
objective. 
Given that endothelial cells release a plethora of molecules in the extracellular 
environment, a challenging part of this work was the identification of the soluble factor(s) 
that might account, at least to some extent, for the promotion of OCSC traits. In this 
context, we reported that L1 induces the expression and secretion of IL-6 by luEC 41, and 
IL-6 represented a good candidate since it promotes the CSC phenotype in several tumor 
types 132,133. Indeed, the depletion of IL-6 from luEC-L1-derived CM abolished its ability 
to promote ID8 sphere formation, demonstrating that this molecule secreted by ECs plays a 
critical role in determining CSC traits also in OC. 
The novel role of vascular L1 in orchestrating the OCSCs features strengthens the rationale 
for testing L1 as a target to develop innovative therapies. Indeed, the neutralization of 
vascular L1 might have a synergistic effect blocking tumor-associated angiogenesis and at 
the same time preventing the persistence of CSCs in patients after chemotherapeutic 
treatment. Indeed, one of the factors that might account for tumor relapse in OC patients is 
the resistance of this subpopulation of cells to the standard chemotherapy, due to their slow 
dividing rate and their ability to actively pump out such drugs 44. 
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In summary, my work has demonstrated: 
• a functional role of L1 in OC-associated vasculature; 
• a crosstalk between L1 and FGFR in endothelial cells; 
• a critical role of vascular L1 in promoting the selection/maintenance of OC 
initiating cells in vivo; 
• the ability of the secreted molecule IL-6 to act as a vascular L1 effector in 
promoting OCSC features. 
 
Collectively, this research might pave the way for exploring the clinical relevance of L1 
expression and function in OC vessels and its crosstalk with tumor cells, possibly opening 
new avenues for the development of novel targeted therapies for OC malignancy. 
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Con la forma ora basta, 
è il momento di mettere le mani in pasta. 
Non sono brava con le smancerie  
ma il mio GRAZIE deve arrivare fino alle periferie. 
 
Tocca al primo della lista 
visto che è lui che mi ha lanciato in questa pista. 
Siamo alla fine e si può dire, 
ce ne fossero di capi come lui a non finire. 
Sempre presente e pieno di sapere 
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non esiste cosa che non riesca a prevedere. 
Su qualcosa è un po’ intransigente: 
manca sempre un controllo, quello più pertinente. 
E te che ti eri impegnata, 
fai la fine della neo-laureata 
e ti chiedi come mai 
quello giusto non lo becchi mai! 
Un altro puntiglio va svelato, 
ecco l’errore che non avevi rivelato: 
dopo attente letture e riletture  
ti sei illusa che non ci fossero brutture. 
Ma lui, basta che apra il primo foglio 
ed individua un bell’imbroglio. 
Cerchi svelta la giustificazione, 
ma poi capisci che sarà il primo di una serie 
e ti arrendi alle tue miserie. 
A parte questo non ci si può lamentare 
e non posso fare altro che ringraziare, 
tante cose mi hai insegnato, 
e a questo mondo mi hai appassionato. 
 
Ora tocca alle colleghe, 
ormai sono amiche e quelle vere. 
Tocca ora alla Lupiaaaaa, 
e meno male che il vento non me la ha mai portata via. 
Quando da Milano me ne andrò, 
qualche sassolino in tasca ti metterò 
così anche i miei successori, 
potranno godere di tutti i tuoi consigli migliori. 
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Dovete sapere che delle cellule è la regina, 
le passerebbe dalla sera alla mattina. 
Per i western invece vi conviene andare altrove 
a meno che non vi divertiate a fare molte prove. 
Sembra un tipo solitario ma nonostante le sue intenzioni, 
non mi sono MAI arresa alle sue poche interazioni. 
Ti ho capito cara bella, niente baci e coccoline 
ma alla fine mi vuoi bene quasi come alle tue nipotine. 
 
Ecco ora Ale Willa, 
sempre a ridere e sempre arzilla. 
Nonostante la tua dipartita 
hai sempre un posto di rilievo nella mia vita. 
Abbiamo iniziato con fagi e purificazioni 
e poi un cambio di intenzioni 
sepolte tra pancreas e topolini 
ci siamo divertite come due cittini. 
E anche se tra i crucchi sei finita 
resteremo sempre e solo NOI le tue colleghe 
e per tutta la vita! 
 
Qualche rima anche per il nuovo arrivato, 
da Cosenza si è palesato. 
Sei stato un bel sostegno 
soprattutto nella stesura della tesi,  che è un bell’impegno! 
La mia mancanza anche dopo il PhD non sentirai, 
con me e lupis tutti i santi imparerai. 
Per non parlare del toscano, 
non ci telefonerai più al ristorante 
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ma lo chiamerai come una persona importante. 
 
Alla fine a tutti gli altri un grande grazie, 
perché avete condiviso le mie gioie e le mie disgrazie! 
Grazie a GB che ha l’occhio brevettato 
e in letture e colorazioni è specializzato. 
Sono indietro di qualche ricciarello, 
ma rimedierò e magari anche con il brunello.  
Grazie a Fabri per le analisi, 
senza di te la statistica mi avrebbe fatto venire una paralisi. 
Sul disordine mi puoi ancora rimproverare, 
perché ho sempre tanto da imparare. 
Grazie a Ste e MIC per il vostro buon umore 
e per essere disponibili anche per me a tutte lo ore. 
Grazie Stefinco per il tuo aiuto costante, 
sei una garanzia e un amico strabiliate. 
Grazie anche Stefina e a Rosmarina, 
garantiscono risate dalla sera alla mattina. 
Grazie anche a tutti gli altri, 
non vi nomino e non è maleducazione 
ma per evitare che i ringraziamenti diventino un sermone. 	  	  
 
 
 
 
